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1 Zusammenfassung/ Abstract 
1.1 Zusammenfassung 
Krebszellen sind durch eine weitgehende Unabhängigkeit von Wachstumsfaktorstimuli und 
eine starke Überaktivierung von wachstums- und überlebens-promovierenden 
Signalübertragungssystemen gekennzeichnet. Auch die verminderte Expression der Sprouty 
(Spry) Proteine trägt nachweislich in malignen Tumoren verschiedener Gewebe zu diesem 
Phänotyp bei. In normalen Zellen fungieren die Spry Proteine, hauptsächlich über ihre 
hemmende Wirkung auf die Ras/Raf/MAPK Signalkaskade, als Modulatoren von Rezeptor-
Tyrosin-Kinasen-aktivierten Signalwegen. 
In dieser Arbeit konnten wir zeigen, dass die Expression von Spry2, aber nicht von Spry1, im 
Nicht-kleinzelligen Lungenkarzinom (NSCLC) im Vergleich zum normalen adulten 
Lungenepithelium signifikant reduziert ist. Basierend auf dieser Erkenntnis, untersuchten wir 
den Einfluss der Spry2 Expression auf den malignen Phänotyp von NSCLC in Abhängigkeit 
von wildtyp (wt) und konstitutiv aktivem K-Ras. Während die verminderte Aktivität der 
MAPK Kaskade und die herabgesetzte Geschwindigkeit der Zellwanderung nach ektopischer 
Expression von Spry2 ausschließlich in K-Ras wt Zellen beobachtet wurde, war die 
Hemmung von Zellvermehrung und Tumorformation in der Maus bei der Re-expression von 
Spry2 unabhängig vom K-Ras Status. Die gewonnen Daten legen nahe, dass Spry2 neben der 
Ras/Raf/MAPK Kaskade eine zweite regulatorische Funktion wahrnimmt. Erhärtet wird diese 
Annahme durch Versuche mit einer Spry2 Mutante, die zwar nicht in der Lage war die 
Signalintensität der MAPK zu inhibieren, aber dennoch signifikant, wenn auch schwächer als 
Spry2 wt, die Zellvermehrung hemmte. 
Da alle Sprouty Proteine als Teil einer auto-regulatorischen Rückkoppelungsschleife 
beschrieben wurden, untersuchten wir in weiterer Folge die molekularen Grundlagen der 
Expressionsregulation verschiedener Spry Familienmitglieder. Erhöhte Spry2 und Spry4 
Levels korrelierten signifikant mit der Expression von aktiviertem endogenen und ektopisch 
expremierten K-Ras in NSCLC-Zelllinien bzw. nicht-malignen Fibroblasten, während Spry1 
nicht erhöht vorgefunden wurde und nicht direkt durch Ras-induzierte Signalwege reguliert 
wird. Durch die Verwendung verschiedener Wachstumsfaktoren und spezifischer Ras 
Mutationen konnten wir weiters zeigen, dass Spry2 hauptsächlich über aktivierende Ras/ Erk 
Signale reguliert wird, während bei Spry4 die Induktion der Spry4 Expression fast 
ausschließlich durch Serum angeregt und über mehrere Ras-aktivierte Signalwege beeinflusst 
wird. 
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Bezüglich der Expressionsmuster während eines Zellzyklus zeigten alle untersuchten Spry 
Familienmitglieder phasenspezifisch fluktuierende und voneinander merklich 
unterschiedliche Expressionsprofile. Außerdem legen unsere Daten nahe, dass Spry1 und 
Spry2 über die Ebene der Transkription reguliert werden, da mRNA und Proteine 
übereinstimmend voneinander exprimiert vorliegen. Im Gegensatz dazu wird Spry4 eher 
durch post-translatorische Mechanismen stabilisiert. Über die exogene Expression von 
wildtyp und dominant negativem cCbl untersuchten wir den Einfluß von cCbl auf die 
Zellzyklusphase-abhängige Expression von Spry1, 2 und 4, v.a. zwischen später G1 und 
früher S Phase. Dabei konnten wir zeigen, dass die Herunterregulation von Spry2 während 
dieses Phasenfensters durch cCbl erfolgt, während Spry1 und Spry4 keine direkten Substrate 
von cCbl sind. 
Zusammenfassend, Spry2 wirkt der Erk Phosphorylierung entgegen und wird selbst durch Ras 
über den MAPK Signalweg induziert. Weiters inhibiert Spry2 die Zellproliferation über einen 
noch nicht beschriebenen Signalweg. Außerdem konnten wir zeigen, dass verschiedene Sprys 
über unterschiedliche Mechanismen in verschiedenen Zellzyklusphasen induziert werden. Auf 
Grund dieser Erkenntnisse liefern unsere Daten einen wichtigen Beitrag zum Verständnis der 
Rolle von Spry Proteinen, vor allem im Hinblick auf ihre Rolle in der Krebsentstehung und -
progression. 
 
1.2 Abstract 
Self sufficiency of growth signals and desensitized signal transduction systems are hallmarks 
of human cancer. One group of proteins shown to be deregulated in malignant tumors of 
diverse tissues are members of the Sprouty (Spry) protein family. Sprys function as 
modulators of receptor tyrosine kinase (RTK) signaling mainly by interfering with the 
Ras/Raf/mitogen-activated protein kinase (MAPK) cascade as part of an auto-regulatory 
feedback loop. 
In this study, we show that Spry2, but not Spry1 expression, is consistently lowered and 
significantly reduced in non–small cell lung cancer (NSCLC) compared to the normal adult 
lung epithelium. Based on this finding, we investigated the influence of Spry2 expression on 
the malignant phenotype of NSCLC cells in the background of wild type (wt) or constitutive 
active K-Ras. Ectopic expression of Spry2 antagonized extracellular-regulated kinase (Erk) 
activity and cell migration just in K-Ras wt cell lines. In contrast, inhibition of cell 
proliferation and tumor formation in mice in response to Spry2 re-expression was observed 
____________________________________________________ Zusammenfassung/ Abstract 
 8
independently of the K-Ras status. In corroboration, a Spry2 mutant unable to inhibit MAPK 
phosphorylation still reduced cell proliferation significantly but less pronounced compared 
with the Spry2 wt protein. 
Since all Sprouty proteins had been suggested to be regulated as part of an auto-regulatory 
feedback loop, further experiments were designed to explore the precise requirements for 
induced expression of the Spry proteins. Increased Spry2 and Spry4 levels significantly 
correlated with the expression of activating endogenous and ectopic expressed K-Ras 
muations in NSCLC cells and non-malignant fibroblasts, whereas Spry1 was not found 
elevated and was not regulated directly via Ras-mediated signaling cacades. Using different 
growth factors and ectopic expression of Ras mutant forms, our data revealed that induction 
of Spry2 is exclusively dependent on Erk activation via Ras-dependent signaling, while 
induction of Spry4 expression was almost exclusively activated by serum and/or several Ras-
influenced signaling cascades. 
Throughout the cell cycle all investigated Spry proteins showed clear and reproducible 
fluctuations, but interestingly their cell cycle-specific expression patterns differed markedly. 
Further, we demonstrate that Spry1 and Spry2 levels are mediated by transcriptional 
activation, since mRNA and protein levels were found coregulated, while Spry4 is stabilized 
by post-translatory modifications. Finally, we investigated the influence of ectopically 
expressed wildtype and dominant negative cCbl on the cell cycle-specific expression of 
Spry1, 2 and 4, especially between late G1 and early S phase. Our data indicate that Spry2 
downregulation within this specific time-frame is mediated by cCbl, whereas Spry1 and Spry4 
are not direct substrates of cCbl. 
Summarizing, Spry2 antagonizes Erk phosphorylation and is itself induced by Ras via MAPK 
activation. Furthermore, Spry2 inhibits cell proliferation by another yet unidentified pathway. 
In addition, we showed that Sprys are induced by different mechanisms, during different 
phases of the cell cycle and are independently deregulated in tumor cells. Therefore our data 
make an important contribution to understand the role of Spry proteins.
_________________________________________________________________ Introduction 
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2 Introduction 
2.1 Deregulated signaling in cancer 
Cancer is a multi-step process developing as a consequence of stepwise accumulation of 
mutations in several genes. The modern definition of a neolastic cell is one that has clonally 
expanded as a result of somatic mutations1, 2. Since cancer is not caused by a single gene 
defect, each mutation contributes to malignancy3 and each new step leads to a clonal 
expansion of cells harboring the new mutation: in this way the probability that multiple 
mutations occur in the same cell is greatly increased4. The first somatic mutation that causes a 
clonal expansion initiates the neoplastic process2. Subsequent somatic mutations result in 
additional rounds of clonal expansion-tumor progression1. The clonal evolution model 
involves mutations in three major types of genes, which are required for a selective advantage 
to the neoplasm over adjacent normal cells. Among the first group are genes taking part in 
both positive and negative regulation of cell growth and survival2. Within the second group, 
genes and their respective protein products are involved in genetic stability regulating DNA 
synthesis and repair and control processes responsible for mitotic recombination and 
chromosomal segregation. Alterations in the mitotic process lead to chromosome 
rearrangements and aneuploidy observed in nearly all solid tumors5. Aneuploidy itself 
increases the possibility for further gains or losses of chromosomes during the mitotic 
process6 and to a higher mutation rate in other genes7. The third group mediates tumor 
invasion and metastasis: abnormalities in cell adhesion proteins, proteolytic enzymes that 
enhance the capability to invade adjacent tissues and changes molecules associated with blood 
clotting and angiogenesis8, 9. 
Oncogenes and tumor suppressor genes function similarly at the physiologic level and 
alterations lead to a selective advantage during the clonal selection process. Oncogenes are 
mutated to render genes constitutively active or active under conditions in which the wild-
type gene is not and can result from chromosomal translocation, gene amplification and 
mutations of crucial residues within the coding sequence. Usually one mutated allele of an 
oncogene is sufficient to confer a selective growth advantage. Alterations within tumor-
suppressor genes reduce their activity to inhibit tumor formation and result from missense 
mutations, truncated versions, deletions and insertions or epigenetic silencing. Mutated cancer 
genes enhance net cell growth, but there are many fewer pathways than genes and 
mammalians have multiple safeguards to protect the cell. Since intracellular pathways 
intersect at multiple levels they cannot be considered separately. For example, several genes 
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directly control transitions from resting stage (G0, G1) to replicating phase (S) of the cell 
cycle: cyclin-dependent kinase 4 (CdK4), CyclinD1 which activates CdK4, the transcription 
factor retinoblastoma (Rb) and p16 (inhibits CdK4)10-12. Genes-encoding p16 and Rb are 
tumor suppressor genes inactivated by mutation, whereas mutations in CdK4 and Cyclin D1 
are activating those oncogenes. There is leading evidence that these four genes function in a 
single pathway in human cancer and show an “exclusivity” principle: since the functional 
effect of each mutation is similar only one of the four genes is usually mutated. 
Further, solid tumors consist of two compartments – neoplastic epithelial cells and 
surrounding stroma cells. During the last years it became evident that the stroma participates 
in many supportive functions such as angiogenesis and plays an active role in tumorigenesis13. 
Usually, cell maintenance and intracellular communication is precisely coordinated by 
positive and negative feedback loops providing the cells with the ability to adjust its output in 
response to monitoring itself. Further, spatial regulation of signaling events are also regulated 
by feedback loops14. Therefore such feedback loops are very often found deregulated in 
neoplastic lesions. Negative feedback occurs when e.g. a signal induces the expression of its 
own inhibitor to limit and/or dampen signaling. In healthy cells, p53 is maintained safely 
beyond its functional threshold by action of a negative feedback involving Mdm2, whose 
transcription is activated by p5315, 16. Since p53 mediates cell-cycle arrest and/or cell death 
upon damage, cells that cannot escape the Mdm2/p53 feedback loop are in danger of losing 
control of normal growth and development as they cannot respond to potentially carcinogenic 
damage and subsequently, the activity of p53 is lost in the majority of human cancers17. A 
signal activating positive feedback loop amplifies/stabilizes the initial signal to prolong 
signaling. Thus, a number of tumors contain amplified or overexpressed Mdm2, which is 
sufficient to block the response of wild-type p53 upon damage and also leads to tumor 
progression. Other examples are autocrine, positive feedback loops which mediate the 
induction of expression of more signaling molecules through the activation of intracellular 
signaling kinases. 
 
2.1.1 Receptor tyrosine kinase-mediated signaling 
Signal transmission cascades are usually initiated by a specific extracellular polypeptide 
ligand binding to membrane spanning cell surface receptors. Receptor tyrosine (Tyr) kinases 
(RTKs) play an essential role in the complex network of cell communication by converting 
extracellular signals into intracellular ones. They control fundamental processes including cell 
cycle, cell migration, cell metabolism, cell survival, cell proliferation, cell differention and 
_________________________________________________________________ Introduction 
 11
hence tissue homeostasis. They are transmembrane glycoproteins that consist of an 
extracellular ligand binding domain, a membrane-spanning transmembrane helix and a 
cytoplasmatic domain with a conserved protein kinase domain core subjected to 
autophosphorylation and phosphorylation by heterologous protein kinases18, 19. The 
polypeptide ligands for RTKs, mostly growth factors, comprise a large variety of different 
signal proteins which act as local mediators at very low concentrations (10-9 – 10-11 mol/L). 
Ligand binding to the corresponding receptor induces the formation of RTK dimers or 
oligomers, or causes conformational change of already preformed receptor complexes and 
leads to RTK activation by cross-phosphorylation (autophosphorylation) of the neighboring 
cytosolic kinase domain. 
 
 
Figure 1 Structure of diverse RTKs20 
 
Tyr phosphorylation within the kinase domains increases the enzymatic activity and catalyzes 
the transfer of the γ-P of ATP to hydroxyl groups of Tyrs to activate specific proteins19. 
Further, autophosphorylation of Tyr residues outside the kinase domain creates high-affinity 
binding sites which are targeted by Src homology region 2 (SH2)- and phospho-tyrosine 
binding (PTB)-interacting motifs found in adaptor proteins, such as growth factor receptor-
bound protein 2 (Grb2) and fibroblast growth factor receptor substrate 2 (FRS2)21. Under non-
malignant conditions, RTKs are under tight control, since these phosphorylation binding 
domains are also recognized by proteins leading to receptor downregulation. One example is 
the casitas B-lineage lymphoma (cCbl) protein which targets activated epidermal growth 
factor receptor (EGFR) promoting ubiquitination and degradation22. Nevertheless, RTKs were 
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found to play a decisive role during carcinogenesis. Many of the known RTKs have been 
found either mutated or overexpressed in human cancers20. 
Downstream-signaling cascades drive tumorigenesis through coordinated phosphorylation of 
proteins regulating protein synthesis, cell-cycle progression and metabolism, and of 
transcription factors that induce the expression of genes involved in these processes4, 23. 
The best known signaling cascades activated by RTKs and often found deregulated in cancer 
are the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase 
(PI3K) pathway with the Ras protein, functioning as the major integrator between 
extracellular signals and intracellular response. 
 
2.1.2 Ras and Ras-induced pathways 
Ras genes were identified as retroviral oncogenes in the 1960/70s from the genome of Harvey 
and Kirsten rat sarcoma viruses24, 25. During the 1980s Ras activating mutations were 
identified in human tumors leading to intensive studies concerning Ras-mediated signaling. 
Today, it is estimated that 20% of all human tumors have activating mutations in one of the 
Ras genes. Germline mutations in Ras pathway-genes result in phenotypically overlapping 
neuro-cardio-facial-cutaneous developmental syndromes26: Neurofibromatosis Type I, 
Noonan syndrome, LEOPARD syndrome, Cardio-facio-cutaneous syndrome and Costello 
syndrome27, 28. In general, patients are characterized by facial dysmorphisms, heart defects 
and short stature, skin and genital malformations, mental retardation, and predisposition to 
certain malignancies26. 
Ras belongs to a large family of monomeric guanosine triphosphotases (GTPases) functioning 
as switches between an active GTP and an inactive, non-promoting conformation. Hexa-
coordinated Mg2+ within small G-proteins provides tight association with guanine nucleotides 
(dissociation constants of GDP and GTP - KD~10-100pM) 29. Two so called switch regions of 
Ras undergo dramatic structural changes depending on the type of bound nucleotide: switch 
region I (aa 30-38) and switch region II (aa 59-67). Upon GTP-binding these two domains 
form a surface for effector molecule binding30. Ras has a measurable intrinsic GTPase activity 
(GTPase hydrolysis rate constant 0.028/min) 31, but GTPase accelerators – GTPase activating 
proteins (GAPs) - increase GTPase activity 105-fold32. Recharge is catalyzed by guanine-
nucleotide exchange factor (GEF) activity generating RasGTP. Activated RTKs are targeted 
by Grb2 which recruits son of sevenless (Sos)-GEF to the plasma membrane as a result of its 
constitutive interaction with Grb2. Upon Ras binding, Sos is maintained in an autoinhibitory 
state. At first, RasGDP binds Sos at an allosteric site distal to the catalytic domain to induce 
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low GEF activity33-35. The generated RasGTP then binds with higher affinity to the same 
allosteric Sos domain to fully relieve steric occlusion of the active site inducing high GEF 
activity36, 37. Significantly, activating mutations in Sos have been identified in patients with 
Noonan’s syndrome38, 39 highlighting the role of Sos in regulating duration, amplitude and 
output of Ras signaling 40. General Ras expression was shown to be modulated by small non-
coding RNAs (microRNAs), e.g. the microRNA let-7, downregulating Ras mRNA at a post-
transcriptional level41, 42. 
Ras isoforms were found localized at various intracellular membranes including Golgi, 
endoplasmic reticulum (ER) and endosomes43-45. Different localization is mediated by post 
translational modification (farnesylation and carboxymethylation) of the hypervariable c-
terminal region of Ras and influences strength, duration and the functional diversity of Ras 
proteins46-48. In H-Ras and N-Ras the hypervariable cysteine-rich region is palmitoylated and 
constantly shuttles between Golgi and plasma membrane upon de-/repalmitoylation cycles49, 
50. In contrast, K-Ras possesses a region of polybasic amino acids and primarily localizes to 
the plasma membrane, but when phosphorylated re-localizes to other endomembrane 
compartments (ER, mitochondria, Golgi)51, 52. Further, spatio-temporal activation, specifity 
and intensity of Ras signaling is influenced by distinct microdomains such as lipid rafts and 
caveolae within the plasma membrane53. 50% of GDP-H-Ras is localized to caveolae and 
upon activation GTP-N-Ras and GTP-H-Ras are mostly located to lipid rafts, while K-Ras is 
not predominantly localized to lipid rafts irrespective of its activation status54, 55. Additionally, 
Ras proteins are differently expressed in diverse tissues and probably exhibit cell type- and 
tissue-specific functions. In mice, H-Ras is highly expressed in brain, muscle and skin and 
lowest in liver, while K-Ras is readily detected in gut, lung and thymus. N-Ras is primarily 
expressed in testis and thymus56. Although mutated Ras genes produce the same phenotypes 
in vitro, altered K-Ras proteins are prevalent in tumors of epithelial origin such as colon57, 
lung58 and pancreatic56 tumors, H-Ras in bladder carcinoma59, 60 and N-Ras is often found 
mutated in liver cancer61 and tumors of the hematopoetic system62. Interestingly, knock-out 
studies in mice revealed viable phenotypes when H- or N-Ras expression is lost, whereas lack 
of K-Ras is embryonically lethal63-66. 
Somatic and germline mutations in all Ras proteins have been found at residues 12, 13, 59, 61 
with position 12, 13 and 61 being the most common67, 68. The substitutions prevent the 
intrinsic and GAP-catalyzed hydrolysis of GTP leading to constitutively active Ras69. Wild-
type G12 and G13 are required for proper insertion of the positively charged “arginine finger” 
of GAP to neutralize and cleave the bond between β and γ-phosphate of GTP. RasQ61 is 
_________________________________________________________________ Introduction 
 14
located within the switch II domain (Q61 is the most conserved residue among all small G-
proteins) and activates H20 to target the γ-P of GTP70. Prolonged activation of Ras is also 
achieved by other mechanisms than Ras mutations: e.g. mutated Ras-GAP neurofibromin-1 
(NF1) (interestingly, none of the other 12 identified RasGAPs have been found mutated in 
human cancer)71 and reduced expression of a let-7 microRNA42. Next to activating mutations, 
also dominant negative Ras isoforms were characterized in vitro. Through mutations in codon 
15, 16 and especially serine (Ser) to asparagines in codon 17 the coordination to Mg2+ is 
weakened and the RasGDP-GEF complex is stabilized and inhibits downstream effector 
protein binding. Overexpression of S17N mutants inhibits the functions of wild-type (wt) 
protein by sequestrating GEF proteins72-74. 
Ras is a general linkage protein and plays a major role in intracellular signaling cascades by 
activating different downstream effector proteins, such as Raf kinase, PI3K and RalGDS. 
 
 
Figure 2 Downstream effector pathways of Ras4 
 
All Ras proteins can interact directly with Raf family kinases. Raf is maintained in an auto-
inhibited state within the cytosol with the N-terminal domain preventing the activity of the C-
terminal kinase domain. 14-3-3 dimers bind to phosphorylation sites of Raf to stabilize the 
auto-inhibited state75, 76. RTKs mediate phosphorylation, as well as Ras-binding, release of 
14-3-3 and membrane lipid interaction to disrupt auto-inhibition of Raf and stabilize the 
active conformation of the kinase domain21. Different Ras proteins activate Raf with various 
intensities. K-Ras is the most potent activator of c-Raf, followed by N- and H-Ras77. Several 
_________________________________________________________________ Introduction 
 15
mutations in one of the Raf isoforms have been characterized: e.g. B-Raf has been found in 
over 60% of malignant melanomas and rarely in colon, thyroid and lung tumors78. 
Once activated, all Raf family members activate mitogen-activated protein kinase (MAPK) 
cascade simply by phosphorylating mitogen-activated protein kinase-kinase MEK and 
consecutively extracellular-regulated kinase (Erk) residues in their respective kinase 
domains79-82. MAPK scaffolds, such as the leucine-rich repeat protein Sur-883, act as docking 
platforms84, 85 to facilitate MAPK activation and provide specifity. Once activated, Erk 
translocates into the nucleus and activates the transcription of a set of immediate early genes, 
such as Myc, Ets, c-Fos and c-Jun. 
 
 
Figure 3 RTK-Ras-ERK signaling cascade21 
 
Another effector pathway of Ras activates PI3K-mediated signaling86. Usually Ras plays a 
minor role in mediating PI3K downstream responses from RTKs87, while oncogenic Ras 
efficiently activates PI3K88. Notably, H-Ras is a more potent activator of PI3K than K-Ras89. 
PI3Ks, assembled by the p110 catalytic and an adaptor/regulatory (p85α, β and p55γ) subunit, 
mediate the phosphorylation of the 3’-OH group of the inositol ring in phospholipids. The 
major pathway of PI3K activation is initiated by phosphorylated RTKs, which are targeted by 
the SH2-containing adaptor subunit of PI3K leading to allosteric activation of the catalytic 
subunit. Alternatively, but insignificant under normal conditions, Ras-GTP can induce the 
p110 subunit of PI3K. Activation of PI3K results in production of phosphatidylinositol 3, 4, 
5-triphosphate (PIP3), out of which 5’-inositol lipid phosphatases further generate 
phosphatidylinositol 3, 4-biphosphate (PIP2). Both are targeted by highly-basic pleckstrin-
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homology (PH)-containing domains, found in 3’-phosphoinositide-dependent kinase-1 (PDK-
1) and Akt/protein kinase B (PKB) (summarized in20). 
PKB/Akt is assembled by an N-terminal PH domain, a central kinase domain (Thr308) and a 
regulatory (Ser473) C-terminus. PDK-1 activates Thr308-Akt90. When Akt is targeted to the 
inner membrane it is activated by constitutive active PDK-1, which is consequently localized 
at the plasma membrane showing a 10-fold higher affinity to PIP3 than Akt. Upon Ser473 
phosphorylation, Akt translocates to the nucleus and is involved in mediating the transcription 
of specific genes to regulate cell survival (Forkhead transcription factors, pro-apoptotic Bcl-2 
family member Bad and the cyclicAMP response element-binding protein (CREB)), cell-
cycle progression (including Cyclin D1), cell growth and cell metabolism (including protein 
synthesis and glycogen metabolism)91. 
Mutations in PI3K pathway components account for 30% of all human cancers23, including 
gene amplification of p110PI3K and Akt in ovarian, breast and pancreatic tumors23, 92-94 and 
p85PI3K mutations in colon and ovarian tumors95. Nevertheless, inactivation of Phosphatase 
and Tensin homolog (PTEN)-protein mainly accounts for deregulated signaling via the PI3K 
pathway and is thought to be the second most mutated tumor suppressor in humans after p534. 
PTEN dephosphorylates the 3’-OH position of the inositol ring in PIP3 and PIP2. 
Consequently, loss of function of PTEN leads to overactivity of Akt through accumulation of 
PIP3 and PIP2 and mutations are detected in a high percentage of human tumors, including 
breast, ovarian and colon cancers and glioblastoma96. Germline mutations of PTEN were 
found in Cowden’s disease and Bannayan-Zonana syndrome97. 
Downstream of Akt, activation of mTOR induces the phosphorylation of the inhibitor 
eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP) to release eIF4E. 
Subsequently, eIF4E initiates protein translation of highly structured 5’-untranslated regions 
found in the mRNA sequences of c-Myc and CyclinD1 involved in cell cycle progression. 
Using the mTOR inhibitor rapamycin, mTOR was also shown to regulate transcription of c-
Myc and activation of signal transducer and activator of transcription (Stat) 3 and PKCs. 
P70S6K, activated by PDK-1, phosphorylates S6 protein of the 40S ribosomal protein subunit. 
Induced S6 drives the translation of 5’-terminal oligopyrimidine-rich tract (5’-TOP) mRNAs, 
which encode for other ribosomal proteins and other components of the translational 
machinery98. Data illustrating that mTOR mediates transformation induced by PI3K and Akt 
through activation of p70S6K and 4E-BP-1, highlights the cooperation between PI3K, Akt, 
p70S6K and mTOR in oncogenesis99. 
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Figure 4 RTK-Ras-PI3K-induced signaling cascade20 
 
Under normal conditions activation of Ras is triggered by external growth factors in a precise-
temporal manner. In primary cells, activated Ras promotes cell-cycle arrest and senescence100. 
In contrast, oncogenic Ras proteins are persistently switched on and mediate the activation of 
diverse downstream pathways. In doing so, Ras effector pathways interact in a concerted 
manner during transformation at least in cell culture models, because each downstream 
pathway activates the transcription of sets of genes regulating cell proliferation and apoptosis 
that are not expressed in normal cells. Such synergistic interactions have been noted for Rho 
and Raf101, PI3K and Raf102, and RalGDS and ERK103. Corroborating, Ras transformation can 
be strongly inhibited by blocking any of these downstream pathways. 
 
2.2 Sprouty proteins 
2.2.1 Sprouty family members 
The members of the Sprouty (Spry) protein family function as regulators of RTK-mediated 
signaling in a receptor- and cell type-specific manner. Their main mode of action was 
described to inhibit MAPK activation in response to RTK/Ras/Erk-mediated signaling104. 
Further, Spry expression was shown to repress branching morphogenesis105, to inhibit 
angiogenesis106-108 as well as cell proliferation 108-112 and migration107-112. The first Spry 
protein to be discovered was the 63kDa Drosophila melanogaster dSpry113. Branchless (Bnl)/ 
breathless (Btl) (homologues of human fibroblast growth factor (FGF)/ FGF receptor (FGFR)) 
signaling plays a key role in activating branching morphogenesis in Drosophila114. Spry got 
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its name from a genetic screen showing that dSpry-/- mutants caused excessive trachea 
branching from the stalks of primary branches close to the tips where secondary branches 
normally divide. Further, the authors could show that dSpry expression itself was induced by 
Bnl signaling or the pointed Ets-domain transcription factor and suggested that dSpry 
localized to the plasma membrane with a small portion being released into the extracellular 
environment and compete with FGF ligand for binding to its receptor113. Subsequent studies 
confirmed that Spry expression is induced by RTK signaling, but located Spry to function 
within the cell as part of a negative feedback loop fine-tuning the activity of intracellular 
signaling pathways105. 
Sprouty homologues were found in Xenopus laevis115, chicken116, 117, zebrafish118, rat119, 
mouse116, 120, 121 and humans113, 122. Murine Spry homologues (termed mSpry1-4) were found 
to be expressed in most fetal and adult tissues: Spry1, 2 and 4 were detected in lung, brain, 
heart, kidney, skeletal muscle, colon, placenta, testis, uterus and limbs, while Spry3 
expression is restricted to brain and testis in adults116, 120-125. In humans, also 4 homologues of 
Drosophila Sprouty were identified113, 120, 123, sharing an unique cysteine-rich C-terminal 
domain and a small, highly conserved N-terminal domain, which are both necessary for Spry 
function. 
Within the N-terminal domain all Spry proteins share a conserved Tyr residue which is 
activated upon RTK-activation promoting interaction with SH2-containing molecules 126-128. 
The rest of the N-terminal sequence diverges within the four Spry proteins. 
 
 
Figure 5 Sequence match of conserved key functional amino acids129 
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Membrane localization of Spry proteins is a conserved mechanism induced by RTK signaling 
126, 128, 130. hSpry2 colocalized with microtubules and translocated to membrane ruffles upon 
growth factor stimulation110, 131. Since membrane targeting was not in all cases dependent on 
N-terminal Spry Tyr phosphorylation127, 128, 132, the C-terminus was shown to be sufficient to 
mediate localization of Spry proteins to membrane structures upon activation where they 
interact with target proteins110, 127, 130, 133. The membrane-binding domain encompasses 
residues 178-221 which binds to PIP2 in vitro and colocalizes with the PH-domain of 
proteinlipase C-γ133. Further it was demonstrated that ectopically expressed Spry1 and 2 are 
modified by palmitoylation which would serve as an anchorage for membrane targeting106. In 
addition, hSpry2 harboring an R252D mutation fails to translocate to the plasma membrane 
and is therefore impaired in its ability to inhibit FGF-mediated signaling133. Accordingly, 
ectopically expressed C-terminal truncated versions of Spry2 are unable to inhibit cell 
migration, cell proliferation and MAPK activation in response to diverse growth factor 
stimuli110, 127. 
 
 
Figure 6 The two functional conserved Spry domains129 
 
2.2.2 Sprouty expression during embryogenesis 
As negative feedback regulators of RTK-signaling, Spry proteins are expressed mainly at sites 
of excessive FGF signaling during organogenesis in mouse, rat and chicken116, 117, 119, 121, 134-
136. During lung morphogenesis, Spry2 was expressed in a spatio-temporal manner in the 
epithelium during lateral outgrowth and in close proximity to known sites of FGF10 signaling 
and in distal airways119, 122, 135. Also Spry1 and Spry4 show overlapping, but not identical 
expressions patterns to FGF10 during organogenesis119, 120. Ectopically implanted FGF10 
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beads upregulated Spry2 expression135 and mediated Tyr phosphorylation of mSpry2, 
membrane localization and increased the interaction with Grb2, FRS2 and Raf in contrast to 
SH2-containing Tyr phosphatase 2 (Shp2) and GAP1137. Accordingly, lower levels of FGF10 
inhibited branching (and decreased Spry2 levels) in the same way as overexpressed Spry2, 
which inhibited epithelial cell proliferation135 and MAPK activation137. Decreased levels of 
mSpry2 using anti-sense oligonucleotides caused excessive branching and increased 
proliferation and the production of surfactant proteins, which play an essential part during 
lung maturation122. Continuous expression of Spry4 during development lead to relatively 
normal lung histology, but reduction in pulmonary lung parenchyma, hypoplastic lungs and 
inhibited vascular development and branching events (lungs with 3 instead of 5 lobes). During 
E12.5-E13.5 lungs were most sensitive to excessive Spry4 in terms of branching and growth, 
whereas overexpression between E16.5-18.5 reduces weight. In vitro, overexpressed Spry4 
inhibited the effect of FGF7138. During brain development in mouse and chicken, Spry1 and 
Spry2 expression overlapped with or was immediately adjacent to expression domains of one 
or more FGF genes and especially apparent to known sites of FGF8116, 117. FGF8 also strongly 
induced Spry2 expression as immediate-early response in chicken134. Furthermore, 
overexpression of mSpry2 and mSpry4 during organogenesis in chicken lead to reduction of 
limb bud size of developing wing and prevented differentiation of proliferation chondrocytes, 
leading to reduction in skeletal element size116. These data also emphasized the evolutionary 
conserved role of Spry proteins as mediators of RTK signaling. 
 
2.2.3 Sprouty gain and knock-out studies 
In Drosophila, dSpry-/- knockout caused excessive trachea branching as a consequence of 
aberrant FGF signaling during development113. In other reports, overexpression and loss of 
function studies of dSpry showed opposing phenotypes during imaginal disc, nervous system 
and wing vein development, respectively and dSpry overexpression especially mimicked 
those effects found in a lost or mutated EGFR pathway background130, 139, 140. In their reports, 
dSpry expression was detected from stage 7 of oogenesis onwards130, 140, which was not 
always dependent on EGFR, but never on Heartless (Htl) and Btl (both homologues of human 
FGFR) signaling. Nevertheless, overexpressed dSpry in embryos inhibited Htl, Btl and 
EGFR-mediated induction of MAPK and the authors suggested additional factors to be 
necessary, depending on the cellular context, to induce dSpry expression. During oogenesis 
removal of dSpry gave rise to phenotypes consistent with hyperactivated EGFR140. During 
wing development dSpry was induced by EGFR signals within the wing veins and dSpry 
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overexpression lead to loss of wing size and reduction or elimination of wing veins130, 140. 
Furthermore, dSpry followed EGFR signaling in the developing eye and follicle cells where it 
inhibited Torso-EGFR-mediated downstream activation. dSpry-/- Drosophila died as pupae 
and had supernumerary photoreceptors, cone cells, pigment cells (non-photoreceptor cells in 
pupal retina) and extra wing veins and overexpression reduced the number of photoreceptors 
in the eye130, 139. Drosophila lacking dSpry further developed phenotypes in the larval 
peripheral nervous system (extra chorodotonal organs) and embryonic central nervous system 
(extra midline glial cells) closely related to those of hyperactivated EGFR. 
Loss of Spry2 in mice caused phenotypes correlated to excessive signaling via growth factors. 
Whereas most of the knock-out mice died within the first weeks, many of the remaining 
survived for at least 6 months, but were significantly smaller than +/+ and +/- littermates141. 
The knock-out mice suffered from esophageal achalasia and intestinal movements defects 
(resembling human Hirschsprung disease) as a consequence of an increased enteric neuronal 
network and hypertrophic ganglion strands. Increased Erk and Akt activation was detected in 
the colon ganglia and at the level of single nerve cells in response to hypersensitivity of the 
enteric nervous system to glial cell line-derived neurotrophic factor (GDNF) and its receptor 
rearranged during transfection (Ret)141. Furthermore, Spry2 -/- mice suffered from hearing 
defects141, 142. Subsequent studies accounted Spry2 with two functions pre- and postnatal in 
the organ of corti. During postnatal differentiation one Deiter’s cell (a progenitor of outer hair 
cells) transformed into an extra pillar cell, because of aberrant FGF8 signaling from adjacent 
inner hair cells, which was the possible cause of deafness. This Spry2 loss phenotype could be 
rescued by decreasing the dosage of FGF8 produced by inner hair cells, suggesting that FGF8 
promotes pillar cell differentiation and Spry2, produced by Deiters’ cells, prevents a Deiters’ 
cell to become a pillar cell142. Furthermore, Spry2 was shown to play a role during 
craniofacial development143, 144. Lack of Spry2 resulted in increased proliferation due to 
enhanced expression of FGF signaling-induced genes in the epithelium and mesenchyme and 
the discoordination of palate growth and morphogenic movements necessary for midline 
contact144. Since cleft palate was also observed in 40% of FGF9 null mice145, 146, the authors 
suggested Spry2 to be a strong candidate to regulate FGF9-mediated signaling. Additionally, 
overexpression of Spry2 before stage 10 resulted in defects in bone architecture and a 
completely open palate with nasal turbinates, whereas at later stages Spry2 overexpression 
caused no defects, resembling a stage-specific role of Spry2 mainly during early stages of 
craniofacial development143. Loss of Spry2 was further associated with malformations during 
teeth development. Spry2 null mice developed an additional diastema tooth in the lower jaw 
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without significantly changing the shape of other teeth. The absence of Spry2 function 
rendered the diastema bud epithelium hypersensitive to FGF signaling from the adjacent 
mesenchyme and maintained expression of sonic hedgehog homolog (Shh)147. Spry2+/- mice 
showed normal dentition. 
Spry4 null mice were viable and fertile and 16% of the investigated mice carried a, mostly 
unilateral, supernumerary tooth, which probably resulted from maintained mesenchymal FGF 
signaling during morphogenesis147. Another report showed that loss of Spry4 function lead to 
reduced body weight and post-natal growth in the F7 generation. Further, they developed 
duplicated digits at the forelimb, but were fertile and harbored no gross abnormalities in any 
other major organ (e.g. no enhanced lung branching). Knock out- and wt-derived mouse 
embryonic fibroblasts (MEFs) showed sustained Erk signaling upon FGF, but not EGF, 
signaling and Spry4 was induced by Wnt-3a in wt MEFs. Spry2/Spry4 double knock out mice 
were embryonic lethal by E12.5 and showed severe abnormalities in craniofacial and limb 
morphogenesis and defects in brain and lung148. 
Loss of function studies focusing on Spry1 revealed that Spry1 is involved in regulating 
ureter-kidney development149, 150. Most Spry1-/- mice died within the first 5 months and 
featured phenotypes of uni- or bilateral ureter (multiple ureters, hydroureter) and kidney 
malformations (nephrons not restricted to cortex, multiple epithelial cysts, several kidney 
primordia fused together) characteristic of the human Congenital Anomalies of the Urinary 
Tract and Kidney (CAKUT) disease149. Further, the renal epithelia in Spry1 null newborns 
exhibited structural and molecular changes characteristic of cystic kidney disease150. It was 
shown that Spry1 functions as feedback antagonist of GDNF/Ret/Wnt11 signals during 
kidney development149, 150. Consequently, lowered GDNF dosages rescued the Spry1-/- 
phenotype149. Furthermore, Spry1 was shown to limit the action of wilms tumor suppressor 
gene 1 (WT1) in the condensing mesenchyme during nephrogenesis and downregulation of 
Spry1 limited the number of nascent glomeruli151. 
 
2.2.4 Regulation of Sprouty function and activity 
Several proteins have been identified to modulate the mode of action of Spry proteins. Most 
reports focused on the role of Spry family members during intracellular signaling within the 
RTK/Ras/MAPK cascade, but contradictorily data have been published to locate the step of 
Spry interference upstream or downstream of Ras (summarized in105). 
In vitro, Spry expression was mostly induced in response to growth factors. Increased levels 
either on mRNA or protein levels were detected upon activation using FGF2, EGF, platelet-
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derived growth factor (PDGF), vascular-endothelial growth factor (VEGF) and hepatocyte 
growth factor/ scatter factor (HGF/ SF)106, 109, 111, 152-154. These growth factors mainly induced 
Spry expression through activation of the MAPK signaling cascade. Correspondingly, it was 
shown that activated Erk is necessary to induce Spry gene expression152. In addition, 
expression of the dominant active, oncogenic Raf1-CAAX caused an increase of Spry2 and 
Spry4 mRNA155. In vivo, transgenic mice expressing the constitutive active K-RasG12D mutant 
showed increased expression of Spry2 in the lung epithelium156. Furthermore, Wnt3a and co-
expression of Wnt7a and Fzd9 upregulated Spry4, but not Spry1 and 2, respectively148, 157. 
Within the N-terminal fraction of Spry proteins a conserved Tyr residue was shown to be 
crucial for its inhibitory action upon phosphorylation mediated by diverse growth factors, 
ectopically expressed RTKs, or Src-like kinases127, 128, 132, 154, 158. Correspondingly, in many 
cases mutations of this specific Tyr to alanine or phenylalanine, respectively, abrogated or 
diminished the functions of Spry proteins in a dominant negative manner on MAPK activation 
and cell proliferation in vitro and in vivo112, 132, 153, 154, 159, 160.  
Promoter studies showed that WT1 directly targets Spry1 promoter and upregulates Spry1151. 
Sequence analysis of the Spry2 and 4 promoter revealed that the functionally important 
proximal region neither contains TATA nor CAAT box but an initiator element around the 
transcription start site146, 161, 162. Several cis-acting elements were shown to be present in the 
proximal region of Spry2, including activator protein 2 (AP2), CREB, stimulating protein 1 
(SP1) and Ets-1161. Further, hepatic nuclear factor 1, SP1, AP2, Elk-1, E47/Thing 1, CCAAT-
enhancer binding protein-β, WT1, sterol regulatory element binding protein , Myc-associated 
zinc finger protein, PBX-1, zinc-finger protein ZF5, Stat5 and hypoxia-inducible factor 1 
(HIF-1) were found in the 5’prime region of Spry4162. However, the factors controlling tissue-
specific expression of Spry genes remain to be identified. 
Only in some cases, decreased Spry levels were observed after growth factor addition. In 
endothelial and NIH3T3 cells, Spry1 mRNA was highest in starved cells and showed 
decreased expression after stimulation106, 109. Spry2 was downregulated by the addition of 
cytokine TGF-β1 and TNF-α by independent mechanisms163, 164. TGF-β1 increased the 
turnover rate of Spry2 via a lysosomal-dependent mechanism and decreased Spry2 
transcription possibly by Smad and TGF-β1-mediated recruitment of HDACs164. TNF-α 
induced downregulation of Spry2 via p38 MAPK signaling on the level of translation. When 
Spry2 was overexpressed, it inhibited TNF-α mediated apoptosis, suggesting that Spry2 plays 
a role in controlling apoptotic action of TNF-α163. 
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In Drosophila, Drk (Grb2 homologue) and GAP1 were shown to bind directly to dSpry130. 
Whereas Grb2 was also found to bind to Spry in mammalian systems, no further evidence was 
reported in the case of GAP1. Some studies described the interaction of ectopically expressed 
isoforms of Spry proteins to be dependent on prior phosphorylation and the sequence 
surrounding the N-terminal conserved Tyr residue, which was targeted by the SH2 domain of 
Grb2, whereas others also detected an interaction in non-activated cells or in cells expressing 
dominant negative Spry, respectively109, 132, 154. A recent report demonstrated that the SH3 
domain of Grb2 specifically targets the PxxPxR motif exclusively found in the C-terminal 
domain of Spry2 which competes with Grb2 binding to the proline-rich domain found in Sos, 
but not FRS2165. Spry2 was further co-localized to FRS2132. In some reports these interactions 
inhibited the complex formation of FRS2-Grb2-Sos (and –Shp2)127, whereas in others theses 
complexes still formed132 in the presence of overexpressed Spry. Spry-Raf interaction was 
described to be enhanced in a FGF signaling-dependent manner137, or mediated via a Ras-
independent mechanism166. In the latter, Spry4 bound to Raf via a conserved C-terminal Raf-
binding domain upon vascular endothelial growth factor receprtor (VEGFR)-mediated PLC-
γ1-PKC pathway activation166. Intracellular phosphatases were also shown to regulate the 
Spry function. Protein-Tyr phosphatase-1B (PTP1B) was increased in the soluble fraction of 
cells in association with Spry2 expression and contributed to the anti-migratory action of 
hSpry2167. Shp2 acts as positive regulator of FGF signaling and dominant active Shp-2 
dephosphorylated mSpry2 and xSpry1 in vitro and in vivo, induced dissociation of both Spry 
proteins from Grb2 and reversed the inhibitory effect of xSpry1 on neurite outgrowth in 
response to FGF stimulation in PC12 cells168. 
 
- Spry + Spry
 
Figure 7 Inhibition of signaling by Spry169 
 
Further complexity was added when it was shown that in mammalians Spry interferes 
differently within FGF- and EGF-mediated downstream signaling. Whereas in all cases, Spry 
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expression inhibited MAPK activation upon FGF stimulation, ectopically expressed Spry 
sustained EGF-induced MAPK induction106, 126, 128, 166, 170-172. These observations are in 
contrast to the above mentioned role of Spry in Drosophila, where it also negatively regulates 
EGFR signaling during development130, 140. This is of special interest since Spry2 is activated 
by Tyr55 phosphorylation (pTyr55) in both ways, but leading to different outcomes126-128, 173. 
In mammalians, the different effect of Spry on EGFR activity was associated on its interaction 
with the ubiquitin E3 ligase cCbl, which mediates protein degradation of protein Tyr 
kinases174. Spry2 was shown to bind to cCbl and Cbl-b in unstimulated, but much stronger in 
EGF-induced cells128, 175.  
 
 
Figure 8  Inhibition of EGF signaling attenuation by Sprouty128 
 
Subsequent studies established three different mechanisms of how Spry2 intercepts cCbl-
mediated EGFR degradation. In the first, Spry2 pTyr55 is targeted by the SH2 domain of 
cCbl. Since the sequence around Spry2 Tyr55 (pYxxxP – also found in EGFR around 
Tyr1045) is a known site for interaction between cCbl and phosphorylated Tyr proteins, cCbl 
initiates poly-ubiquitination and proteosomal degradation of pTyr55 Spry2 instead of 
pEGFR126, 128, 173. In the second mechanism, Spry2 competes with UBCH7, an E2 ubiquitin 
conjugating enzyme which mediates ubiquitination, for binding to cCbl’s Ring Finger 
domain. Further, the interaction between Spry2 and the Ring Finger domain has been 
described as specific, but independent of growth factor signaling171. In the latter way, Spry2-
cCbl interaction is mediated by CIN85172. CIN85 possesses three SH3 domains which bind to 
atypical proline-arginine motifs (PxxxPR) present in the C-terminus of cCbl and Cbl-b. In this 
way, CIN85 clusters Cbl molecules to target activated EGFR for endocytosis and 
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degradation176. Spry2 contains two such motifs and constantly interacts with 2/3 CIN85 SH3 
domains, whereas Cbl joins this complex upon EGF stimulation172. Nevertheless, in all ways 
ectopically expressed Spry2 prolonged EGFR-mediated downstream signaling. Additionally, 
Spry1 was also shown to be a target of cCbl upon growth factor activation, but not Spry4, 
possibly because it lacks crucial residues in the conserved N-terminal domain132. 
Several studies showed direct interaction between all human Spry proteins and the 
serine/threonine testicular protein kinase 1 (Tesk1)123, 177, 178. While it was shown that Tesk1 
kinase activity was not necessary for complex formation177, 178, EGF stimulation increased the 
interaction between Tesk1 and Spry123. Furthermore, it was reported that Tesk1 altered Spry2 
localization to cellular vesicles instead of membrane ruffles and inhibited Spry2 to bind to 
Grb2 upon FGFR1 induction. Therefore Spry2 was not able to reduce MAPK activity and to 
inhibit growth factor-mediated neurite outgrowth in PC12 cells, but Tesk1 did not affect the 
interaction between Spry2 and cCbl to sustain EGFR signaling upon EGF ligand 
stimulation177. On the other hand, Spry4 targeted Tesk1 in a dose-dependent manner to inhibit 
Tesk1-mediated cell spreading. Activation of MAPK was not essential for this mechanism178. 
Notably, due to its different C-terminal domain to Tesk1, no interaction between any member 
of the Spry family and Tesk2 was described177. 
Next to the crucial Tyr55 within the conserved N-terminal box, also other phosphorylation 
sites have been demonstrated to regulate Spry2 function. Additionally to Tyr55, c-Src further 
phosphorylated Tyr residues within the C-terminal domain induced by FGF, but not EGF, 
linked to the inhibitory action of Spry2 on MAPK activation in response to FGF-, but not 
EGF-mediated signaling. Among them, Tyr227 and to a lesser extent also Tyr269 and Tyr283 
mainly contributed to the action of Spry2, but were not involved in Spry2’ cellular 
localization or interaction with Grb2154. In an early report Spry proteins were also subjected to 
serine (Ser) phosphorylation106. Accordingly, Spry proteins were shown to be phosphorylated 
within a Ser-rich domain in the center of the Spry locus upon EGF and FGF signaling179, 180. 
One report demonstrated that MAPK-interacting kinase 1 (Mnk-1) phosphorylates hSpry2 on 
serine 112 and 121 resulting in decreased EGF-induced degradation by cCbl. Furthermore, 
okadaic acid, a specific inhibitor of serine/threonine phosphatases, lead to the accumulation of 
the slow-migrating form of hSpry2. Since okadaic acid was observed to specifically inhibit 
protein phosphatase 2A (PP2A), the authors raised the possibility that hSpry2 might be a 
substrate for PP2A179. This interaction was confirmed by another report proposing a 
mechanism where Spry2 is phosphorylated on Ser112, 115 and 138 in unstimulated cells. As 
a consequence of FGFR1 signaling, PP2A is activated and the interaction with Spry2 
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increased to mediate dephosphorylation of Ser112 and 115 (Ser138 remains phosphorylated). 
FGFR1 on the other hand also mediates phosphorylation of Ser 156, 167, 197, threonine 190 
and Tyr 176 and 190 on Spry2 which thereafter limits FGF-activated MAPK signaling. Then 
cCbl, which competes with PP2A to bind to a specific region between Spry2 residues 50-60, 
mediates Spry2 downregulation. Furthermore, in their report overexpression of cCbl’s Tyr 
kinase binding domain abrogates Spry2 to inhibit FGFR1-induced ERK activation, neurite 
outgrowth and Spry2 is accumulated in the slower migrating band in a Spry2-specific 
immunoblot180. 
At last, Spry family members were reported to complex as homo- and heterodimers132, 153, 
which serves as an additional step to be considered investigating of how Spry proteins 
finetune several RTK-mediated processes. 
 
2.2.5 Role of Spry proteins during neoplastic transformation 
Several studies focused on the role of Spry during tumorigenesis of diverse tissue. Spry1, 2 
and 4 are downregulated in prostate cancer181-183. Reduced levels of Spry2, and in some cases 
also Spry4183 were a direct consequence of silencing by promoter hypermethylation and 
treatment with de-methylating agent 5-aza-2'-deoxycytidine (AZA) increased Spry2 
expression in vitro182. Further, 27-40% of loss of heterozygosity (LOH) was demonstrated for 
Spry2 with tightly flanking markers182. In breast cancer, Spry1 and 2 are consequently 
downregulated by other means than epigenetic silencing and expression of dominant-negative 
Spry2 induced anchorage-independent growth and tumor formation in vivo160. Furthermore, 
Spry2 but not Spry1 was identified to be downregulated in hepatocellular carcinoma 
(HCC)159, 184. It was shown that this was not due to LOH and promoter hypermethylation159. 
Using an in vivo model, expression of dominant negative Spry2 in combination with activated 
∆N90-β-catenin lead to HCC tumor formation in 50% of mice, featuring highly proliferative 
cells, upregulated pErk levels (no effect on pAkt) and induction of cell-cycle specific genes 
such as cyclinB1, D1 and E1184. In lung-derived non-small cell lung cancer (NSCLC) 
overexpression of Spry2 reduced tumor multiplicity and diameter in urethane-induced lung 
tumor development in mice185. In melanoma cells, Spry2 was downregulated in melanocytes 
and wt B-Raf melanoma cells, compared to high levels in dominant active B-RafV599E-
expressing cells186. Induced levels of Spry2 were also found in mice expressing dominant 
active K-RasG12D156. Since ectopic expression of Spry4 failed to inhibit constitutive active 
RasL61-mediated MAPK activation107, these data suggest that Spry proteins counteract RTK-
Ras-MAPK-mediated signaling upstream of Ras and that during carcinogenesis Spry proteins 
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only need to be downregulated in cells featuring unaltered Ras-induced signaling cascades, 
whereas high levels of Spry are tolerated when activating mutations occur at the level or 
downstream the inhibiting mode of action of Spry. 
_____________________________________________________________ Aims of the study 
 29
3 Aims of the study 
 
A considerable body of evidence indicates that alterations in receptor tyrosine kinase (RTK)-
mediated signaling contribute to cancer development and progression. Accordingly, RTK-
induced intracellular signaling cascades have to be tightly regulated via positive and negative 
feedback mechanisms to ensure homeostasis of cells and tissues. The recently discovered 
family of Sprouty proteins was shown to regulate RTK-activated signaling in an 
autoregulatory feedback loop manner. The main mode of action of Spry proteins was 
described to inhibit MAPK activation in response to RTK/Ras/Erk-mediated signaling. 
Different studies described an inhibitory effect of Spry proteins especially during lung 
development. Consequently, loss of Spry lead to aberrant RTK-meditated signaling and lung 
branching morphogenesis. 
Therefore, we chose non-small cell lung cancer (NSCLC) as our tumor model system to 
investigate the deregulation of Spry expression compared to non-malignant lung and to 
elucidate the consequences of exogenous Spry expression on the malignant phenotype of 
NSCLC. Further, we attempted to investigate those growth factor-mediated signaling 
cascades inducing Spry expression in tumor and non-malignant cells. At last we studied Spry 
expression during cell cycle in normal cells. Since all Sprouty proteins were postulated to be 
induced, activated and functional in a similar manner, we further tried to elaborate Spry 
family member-specific differences throughout this study. 
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4 Materials and Methods 
4.1 Competent bacteria 
A single colony of XL1blue or DH5α bacteria taken from a selective LB plate (15g agar/1l 
LB medium - 10g NaCl, 10g Trypton from Casein, 5g yeast-extract, 1l ddH2O) was 
inoculated in 2.5ml LB medium, o/n at 37°C, under constant shaking. The o/n culture was 
sub-cultured 1:100 in 250ml LB medium with 20mM MgSO4 and incubated at 37°C, under 
constant shaking, until its optical density at 600nm (OD600) reached 0.4-0.6. The bacteria 
were pelleted by centrifugation at 4500g, 5’, 4°C. Medium was removed and the pellet was 
re-suspended in 100ml chilled TFB1 buffer (30mM CH3COOK, 10mM CaCl2, 50mM MnCl2, 
100mM RbCl, 15% glycerol, in ddH20, adjust to pH 5.8 with 1M CH3COOH, filter-sterilize 
(0.45µM) and stored at room temperature (RT)) and incubated for 5’on ice. 
For the remaining steps, the cells were always kept on ice, and all pipets, tubes and flasks had 
to be chilled. The bacteria were pelleted by centrifugation at 4500g, 5’, 4°C, re-suspended in 
10ml TFB2 buffer (10mM MOPS, 75mM CaCl2, 10mM RbCl, 15% glycerol, adjust to pH 6.5 
with 1M KOH, filter-sterilize (0.45µM) and stored at RT) and incubated for 15-60’ on ice. 
Afterwards, the aliquots were immediately stored on –80°C. 
 
4.2 Transformation by heat shock 
Competent XL1blue or DH5α bacterial cells were thawed on ice. 50µl were added to 1-10µl 
DNA plasmid solution and incubated for 30’ on ice. Afterwards, a 90’’ heat shock on 42°C 
was performed, 500µl LB medium were added and the bacteria were incubated constantly 
shaking for 1h on 37°C. The bacteria were pelleted by centrifugation at 2500g, 3’ and the 
supernatant (SN) was discarded. The pellet was re-suspended in LB medium and plated o/n on 
selective LB plates (additionally containing either [100µg/ml] Ampicillin, Kanamycin, or 
[25µg/ml] Chloramphenicol, respectively). 
 
4.3 Polymerase Chain Reaction (PCR)-based techniques 
PCR was used to amplify specific regions of DNA adding artificial overhangs used for 
cloning or to introduce mutations by site-directed mutagenesis. 
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PCR used for cloning: PCR mix: 1µl template DNA (10pg-200ng), 0.4µM sense primer, 
0.4µM anti sense primer, 1x AccuPrimeTM Pfx mix, 0.4mM deoxy-nucleotide tri-phosphates 
(dNTPs), 0.5mM MgSO4, 1.25U AccuPrimeTM Pfx DNA polymerase (Invitrogen), final 
volume 50µl ddH2O – cycle conditions: 1 cycle 5’ 94°C, 25 cycles 1’ 94°C, 45’’ 58°C, 1’ 
68°C, 1cycle 10’ 68°C, ∞ 4°C. 
The DNA fragment was either recovered following Agarose gel electrophoresis or desalted 
before restriction digested and cloned into the respective pre-cut vector. 
 
Site-directed mutagenesis: PCR mix: 100ng template DNA, 0.4µM sense primer 0.4µM anti 
sense primer, 1x Phusion HF Buffer, 0.4mM dNTPs, 2U Phusion Hot Start DNA polymerase 
(Finnzymes), final volume 50µl ddH2O – cycle conditions 1 cycle 30’’ 98°C, 25 cycles 10’’ 
98°C, 30’’ 60°C, 30’’/1kb 72°C, 1cycle 10’ 72°C, ∞ 4°C. 
10µl 10xA buffer, 39µl ddH2O and 1µl DpnI (Roche) were added and the mixture digested 
o/n at 37°C. On the next day, transformation by heat shock was performed into competent 
bacteria and the cells were plated onto selective LB plates. 
 
Restriction fragment length polymorphism (RFLP)-Analysis of K-RasG12 mutations: The 
artificial RFLP was performed as described187. Shortly, genomic DNA was isolated in a buffer 
containing 10mM Tris-HCl pH 8, 1mM EDTA, 1%SDS, 200µg/ml Proteinase K (Roche) 
using Precellys 24 Lyser/Homogenisator (Bertin Technologies, Saint-Quentin-en-Yvelines 
Cedex, France) and incubated overnight at 56°C. After phenol/ chloroform extraction, DNA 
was precipitated and stored at -20°C. Exon 1 of K-Ras was amplified (30 PCR cycles) using 
the following primers 5’-ACTGAATATAAACTTGTGGTCCATGGAGCT-3’ and 5’-TTAC 
CCATATTGTTGGATCATATTC-3’ introducing an artificial BstXI enzyme restriction site. 
In case of K-Raswt a second BstXI site was generated. Following restriction digestion using 
BstXI (Roche), DNA was separated via non-denaturating polyacrylamide gel electrophoresis 
(PAGE) using 19:1-acrylamide:bisacrylamide for polymerization and 1xTBE (0.09M Tris-
borate, 0.002M EDTA) as running buffer. 
 
Reverse Transcription PCR: Using Taq DNA Polymerase (Promega) and selective 
oligonucleotide-primers expression levels of transcripts in tumor tissues were determined by 
semiquantitative reverse transcription PCR procedure. Dynamics of PCR amplification were 
evaluated at different PCR cycle numbers and the respective controls were included. 
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4.4 Restriction digestion and cloning 
Restriction digestion: Plasmid restriction digestions were performed following the conditions 
of the manufacturer company (Roche, New England Biolabs). The respective 10x buffers 
were used and diluted 1:10 in the final reaction. According to the amount of applied DNA the 
reaction volume differed between 10-50µl. All other reagents have to be adapted to the final 
volume and the mixture incubated at the indicated temperature. 
 
Agarose gel electrophoresis: Agarose electrophoresis was used to check the accuracy and 
correct size of plasmids and PCR fragments. Therefore, restriction digested plasmids or PCR 
products were mixed with 6x loading buffer (0.25% bromphenolblue, 40% sucrose) and 
separated via agarose gel electrophoresis using 1xTAE as running buffer (0.04M Tris-acetate, 
1mM EDTA), respectively. Afterwards, the gel was stained in a 0.25µg/ml ethidium bromide 
solution and DNA fragments were visualized under the UV screen. 
 
Gel DNA recovery: Under the UV screen (see Agarose gel electrophoresis) the DNA 
fragments were cut out of the gel and purified according to the supplier’s protocol 
(Zymoclean Gel DNA Recovery Kit, #D4002). 
 
Desalting DNA: Mini Quick Spin columns (Roche) were used to desalt DNA fragments after 
restriction digestion and gel recovery or to remove oligonucleotides after PCR reaction. 
Before use, the columns Sephadex G50 matrix was re-suspended by inverting. The cap and 
the bottom tip were removed and the column was centrifuged for 3’, 1000g to pack the 
column and to remove residual buffer. Finally, the sample was added to the column bed. The 
column was centrifuged for 3’, 1000g and the plasmid-containing eluate was collected in a 
tube. 
 
Cloning: Pre-cut vector and insert were ligated according to the manufacture’s protocol 
(Roche Rapid DNA Ligation Kit, #11635379001). After the ligation step, the newly cloned 
plasmid was transformed by heat shock and plated on selective LB plates. 
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4.5 Stetl, MIDI, MAXI and CsCl plasmid DNA purification 
In all cases, isolation of the correct plasmid was checked by restriction digestion using 
restriction endonucleases (Roche, New England Biolabs) and the amount (µg/µl) determined 
via OD260 η-drop measurement. 
 
Stetl Prep: A single clone (see Transformation) was inoculated in 3ml selective LB medium 
o/n at 37°C under constant shaking. The bacteria were pelleted by centrifugation 10000g for 
3’ and the SN was decanted. The pellet was re-suspended in chilled 110µl Stetl-buffer (8% 
Sucrose, 0,5% Triton X-100, 50mM Tris, pH 8, 50mM EDTA and freshly added 0.05% 
Lysozyme (Roche)) and the bacteria lysed by incubation on 95°C, 1’. The bacterial debris was 
pelleted by centrifugation (10000g, 10’, 4°C) and removed with an autoclaved toothpick, 
previously tipped in chilled RNAse solution (10mM Tris, 15mM NaCl, 5% Ribonuclease A 
(Sigma), adjusted to pH 7.55, heated for 15’ at 100°C and stored at –20°C). The DNA in the 
SN was precipitated by adding 110µl of isopropanol, followed by rigorous vortexing and 
centrifugation (15’, 10000g, 4°C). The SN was decanted and the pellet washed twice using 
chilled 70% ethanol. After each washing step the DNA was collected by centrifugation (15’, 
10000g, 4°C). Finally, the pellet was dried under the fume hood and the purified DNA 
resuspended in ddH2O. The DNA solution was stored at –20°C. 
 
MIDI, MAXI Prep: A single clone was inoculated in 100ml (MIDI) or 500ml (MAXI) 
selective LB medium, respectively, o/n at 37°C under constant shaking and the plasmid DNA 
isolated according to the supplier’s protocol (Promega PureYield plasmid MIDI prep system 
#A2492, QIAGEN Plasmid Maxi Kit #12162). 
 
CsCl-Prep: A single clone was cultured o/n in 500ml selective LB medium. The cells were 
pelleted via centrifugation (5000rpm, 5’). The pellet was resuspended in 18ml resuspension 
buffer (50mM glucose, 25mM Tris/HCl pH8, 10mM EDTA pH8.0) and 2ml Lysozyme 
(Roche) solution [10mg/ml] were added. Then, 40ml freshly prepared lysis solution (0.2M 
NaOH, 1% SDS) were added, mixed thoroughly and incubated for 5’-10’ at RT. Then, 20ml 
ice-cold neutralization solution (60ml 5M potassium acetate, 11.5ml glacial acid, 28.5ml 
ddH2O - the resulting solution is 3M with respect to potassium and 5M to acetate) were added 
and immediately mixed by shaking, before incubating for 10’ on ice. The lysate was 
centrifuged for 15’, 4000rpm, 4°C and the collected SN filtered. 0.6 volume of isopropanol 
were added, mixed well and and incubated for 10’ at RT. The nucleic acids was recovered by 
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centrifugation (8000rpm, 15’, RT) and the pellet washed with chilled 70% ethanol. The 
plasmid DNA was resuspended in 5ml ddH2O, 5g CsCl added and incubated for 10’ in a 30°C 
water bath. Next, 0.8ml ethidium bromide (AppliChem) stock solution (10mg/ml in 
ddH2O)/10ml CsCl-plasmid DNA solution was added, mixed and centrifuged for 5’, 
1500rpm, RT. The SN was collected carefully, filled bubble-free into Beckman tubes 
(polyallomer quick-seal centrifuge tubes, #362248) and sealed. A density-gradient 
ultracentrifugation step was performed for 20h, 45000rpm, RT using a Beckmann VTi 65.2 
rotor. On the next day, the DNA was recovered using an 18G needle and filled up to 6ml with 
ddH2O. The ethidium bromide residual was removed by repeating steps of extraction using 
2ml isoamyl alcohol. The upper, aqueous phase was collected and the plasmid DNA 
precipitated by adding 1/10 volume 3M NaOAc, pH5.2 and 2-2.5 volume ethanol abs. for 1h 
at -20°C. Again, the DNA was recovered by centrifugation (15’, 4°C, 13000rpm) and washed 
using chilled 70% ethanol. Finally, the plasmid DNA was resuspended in 0.5-2ml ddH2O. 
 
4.6 Cell culture 
All cell lines used are of human origin and were cultured in the respective medium containing 
10% fetal calf serum (FCS) at 37°C in a humidified incubator with 5% or 7.5% CO2. Every 
second to third day medium was replaced. When the cells had reached 90% confluency they 
were split using trypsine/EDTA (0.1% trypsine (BD), 0.01% EDTA, 0.001% phenol red). 
 
Cell line Site Stage Type Medium Source / Alias 
WI 38 lung  fibroblasts DMEM ATCC - CCL75 
A-427 lung  AdenoCa DMEM ATCC - HTB53 
A-549 lung  AdenoCa RPMI ATCC - CCL185 
Calu-3 lung IV AdenoCa DMEM ATCC - HTB55 
Calu-6 lung  AdenoCa DMEM ATCC - HTB56 
E14 lung III AdenoCa DMEM ICR / VL-1 
SK-LU-1 lung III AdenoCa DMEM ATCC - HTB57 
HZA lung III Large cell RPMI ICR / VL-2 
LPHE lung II Large cell RPMI ICR / VL-4 
AHWG lung II Squamous RPMI ICR / VL-10 
JHWE lung I Squamous RPMI ICR / VL-3 
LSWW lymph node III Squamous RPMI ICR / VL-6 
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MBSJ lymph node IV Squamous RPMI ICR / VL-8 
MCKW lymph node III Squamous RPMI ICR / VL-5 
MSPG lymph node IV Squamous RPMI ICR / VL-7 
ZYGF lung II Squamous RPMI ICR / VL-9 
HEK 293 kidney  embryonic DMEM ATCC – CRL1573* 
CRE8 kidney   DMEM HEK 293-derived 
 
4.7 Construction of adenoviruses 
The construction of adenoviral vectors was based on Cre-lox recombination between a Ψ5 
donor virus and a pADlox vector-containing target insert188. 
 
4.7.1 Preparation of Ψ5 donor virus DNA 
Logarithmically growing HEK 293 (between passage 35-40) cells were cultured on a φ15cm 
plate and infected with 1-2µl Ψ5 donor virus until the cells started to lyse. The cells including 
the SN were harvested and centrifuged for 5’, 1500rpm. The SN was reduced to 5-8ml and the 
cells lysed by repeating cycles of freeze (N2(l)) and thaw (37°C).  
The virus-containing SN was distributed on 15-20 logarithmically growing HEK 293 φ15cm 
plates until the cells started to lyse. The cells were scraped off and collected in polypropylene 
tubes via centrifugation (5’, 1500rpm) and the SN discarded. The pellet was resuspended in 
8ml sterile 10mM Tris, pH8 and the cells lysed by repeating cycles of freeze and thaw. After 
centrifugation, 4.4g CsCl were added to the virus-containing SN and centrifuged for 18-24h, 
32000rpm, 10°C in a Beckmann centrifuge. The Ψ5 donor virus was recovered using an 18G 
needle and aliquots were stored at -20°C. Note: one aliquot should be diluted 1:1 in 2x storage 
buffer (10mM Tris pH8, 100mM NaCl, 0.1% BSA, 50% glycerol) and can be used to 
propagate Ψ5 donor virus in HEK 293 cells. 
A second aliquot was subjected to Proteinase K digestion in a buffer containing 10mM Tris, 
pH8, 1mM EDTA, 1%SDS, 200µg/ml Proteinase K (Roche) at 56°C o/n. After phenol/ 
chloroform (pH 7-8) extraction, DNA was precipitated by adding 1/10 volume 3M NaOAc, 
pH5.2 and 2.5 volumes EtOH abs at -20°C o/n. The virus DNA was recovered by 
centrifugation (30’, 13000rpm, 4°C) and washed with 70% ethanol. The pellet was dried 
under the fume hood and resuspended in ddH2O. The concentration (µg/µl) was determined 
by measuring the absorbance at 260nm. Aliquots were stored at -20°C. 
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4.7.2 Preparation of the target recombinant virus 
3µg of gene-shuttled pADlox plasmid DNA were co-transfected with 1µg Ψ5 DNA (see 
Transfection) into Cre8 cells (ratio pAdlox shuttle plasmid:Ψ5 virus = 3:1). Therefore, the 
day before transfection, 105 cells were plated in a tissue culture plate (φ 6cm). Per plate 200µl 
serum-free medium and 6µl FuGENE 6 Reagent (Roche) were mixed and incubated for 5’ at 
room temperature (RT). Meanwhile, 3µg SfiI-digested pADlox-DNA and 1µg Ψ5 DNA were 
placed in a separate tube, and the FuGene mixture was added and incubated for 15’-45’ at RT. 
Then the reagent solution was added dropwise to 80% confluent cells, cultured in medium 
(10%FCS), distributing it around the well and returned overnight (o/n) into the incubator. The 
medium was changed on the next day. 
When the cells started to lyse, they were scraped off and collected by centrifugation (3’, 
1500rpm). The SN was reduced to about 2ml and the virus was extracted by four to five 
cycles of freeze and thaw. The sample was centrifuged again for 3’, 1500rpm before new 
Cre8 cells were re-infected with less amount of virus-containing SN than before. 
After about five re-infections, fifteen to twenty tissue culture plates (φ15cm) of HEK 293 
cells were infected with an adequate amount of virus (derived from the last Cre8 infection). 
Before the cells started to lyse, they were scrapped off, collected and pelleted by 
centrifugation (5’, 1500rpm). The SN was removed and the cells re-suspended in 8ml of 
10mM Tris, pH8. If not used immediately, the pellet was stored at –20°C. 
Then the pellet was again lysed by cycles of freeze and thaw as before. After centrifugation 
(5’, 1500rpm) the virus containing SN was collected and 4g CsCl added, followed by density-
gradient ultracentrifugation (18-24h, 32000rpm, 10°C) in a Beckmann centrifuge. The purified 
virus was collected from the gradient using an 18G needle, diluted 1:1 in 2x Storage buffer 
and stored in small aliquots on –20°C. 
 
4.8 Clonogenic assay, Growth curve, Scratch assay 
Cells were infected by adenoviruses - multiplicity of infection (MOI) 50 - and cultured in 
their respective medium containing 10%FCS. Two days post-infection the virus was washed 
away and the cells were subsequently cultured in adenovirus-free medium. 
 
Clonogenic Assay: 1-2x103 cells were cultured in a 6-well plate in the respective medium 
(10%FCS) until multicellular clones had formed. The medium was removed and the cells 
washed using 1xPBS (137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4). Then 
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the cells were fixed in Giemsa solution (Merck) by incubating 10’at RT. Afterwards, Giemsa 
solution was removed, the remaining fixation agent removed by rinsing several times with 
ddH2O and dried under the fume hood. A photograph was taken to document the distribution 
and amount of stained clones. 
 
Growth curve: Equal amounts of cells (1-5x104) were plated and counted in duplicates every 
2-3 days, 1:1 diluted in 0.4% trypan blue solution (Sigma), whereas medium change was 
performed for the other plates. 
 
Scratch assay: 2x105 cells were plated in a 6-well plate and cultured until they reached total 
confluence. A scratch was set with a 200µl plastic tip into the cell monolayer. The gap’s 
closure was documented by photomicrographs and the closure velocity (µm/h) calculated 
using MetaMorph 6.1, Universal Imaging Corp. 
 
4.9 Flow cytometry 
Cells were harvested (shock frozen in N2(l) and stored at -80°C until use) and resuspended in 
100µl 1xPBS. Then, 150µl chilled trypsine solution (20.4mM Na-citrate, 0.6% NP-40, 3mM 
Tris, 0.02% trypsine (BD), pH7.6) were added, mixed carefully and incubated for 10’, RT. 
Afterwards, 125µl trypsine inhibitor solution (20.4mM Na-citrate, 0.6% NP-40, 3mM Tris, 
0.3% trypsine inhibitor (Sigma), 0.06% RNase A (Sigma), pH7.6) was added, mixed by 
inverting and incubated for 10’, RT. Finally, propidium iodide-containing solution (1xPBS, 
0.02% propidium iodide (Sigma) was added and incubated for 10’, RT under light protection. 
The cell cycle-specific distribution was measured by flow cytometry (BD FACSCalibur) and 
illustrated using ModFit software. 
 
4.10 Generation of Spry-specific antibodies 
Single colonies of either glutathione S-transferase (pGEX vector)–tagged NH2-terminal 150 
amino acids of human Spry2, NH2-terminal 200 amino acids of human Spry1 and NH2 
terminal 220 amino acids of human Spry4 were inoculated in 50-100ml selective LB medium 
o/n at 37°C under constant shaking. On the next morning, the culture was diluted 1:10 with 
selective LB medium and incubated for 1h at 37°C under constant shaking. Then, isopropyl-β-
D-thiogalactopyranoside (Applichem) was added to a final concentration of 100µM and 
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further inoculated for 2-3h as before. Afterwards, the cells were harvested (10’, 5000rpm, 
4°C) and resuspended in 50ml 1xPBS. A spatula tip of Lysozyme (Roche) was added and the 
mixture incubated for 30’ on ice. Afterwards, TritonX-100 (Fluka) was added to a final 
concentration of 0.5% and sonicated (Bandelin Sonopuls) 5 times for 30’’ at 70% on ice. The 
debris was pelleted by centrifugation (10’, 8000rpm, 4°C, SS-34 rotor). The SN was collected 
and Glutathione Sepharose 4B (GE Healthcare) beads (before use, 400µl beads solution was 
rinsed 3 times with 1xPBS) added. The mixture was incubated head over head at 4°C o/n to 
couple the proteins to Sepharose beads. On the next day, the solution was applied to a Poly-
Prep chromatography column (BioRad, #731-1550) and the beads column matrix washed with 
10ml TNN buffer (50mM Tris pH7.5, 250mM NaCl, 5mM EDTA, 50mM NaF, 0.5% NP-40) 
and 50ml 1xPBS. The beads were transferred to an Eppendorf tube, 500µl 5U Thrombin-
containing 1xPBS added and incubated o/n, head over head at 4°C to release the coupled Spry 
protein fragments from the beads matrix. On the next day, the solution was applied to another 
Poly-Prep chromatography column and the Spry protein antigen (AG)-containing eluate 
collected. Further, the beads were additionally washed with 500µl 1xPBS and a second eluate 
collected. The protein concentration was estimated by PAGE (using 37.5:1 
acrylamide:bisacrylamide for polymerization), followed by coomassie staining (0.25% 
Coomassie Brilliant Blue G250, 10% glacial acid, 30% methanol) in comparison to 0.2, 1 and 
5µg/µl BSA standards. 
600µg of Spry AG were used to raise polyclonal anti-Spry-specific rabbit serum, respectively 
(Eurogentec, 4102 Seraing, Belgium). 
The remaining Spry AG solutions were dialyzed o/n in Coupling buffer (0.1M NaHCO3 pH8, 
0.5M NaCl) at 4°C using a dialysis membrane (Pierce, Slide-A-Lyzer 3.5kDa, #66110) 
according to the manufacturer’s protocol. On the next day the AG solution was bled off and 
filled up to 10ml with Coupling buffer (5ml of were used for antibody purification and the 
remaining half stored at -20°C until use). 0.5g CNBr Sepharose4B (GE Healthcare) was 
activated using 1l 1mM HCl on a suction filter by vacuum filtration and added to 5ml 
dialyzed AG solution. After an incubation time for at least 2h head over head at RT, the AG-
coupled matrix beads were collected by centrifugation (5’, 1500rpm) and washed twice with 
Coupling buffer. Afterwards, 10ml blocking buffer (0.1M Tris pH 8) was added to the beads 
and incubated head over head for at least 1h at RT. Again, the matrix was recovered by 
centrifugation and washed with 3 cycles of washing buffer A (0.1M CH3COONa pH 4, 0.5M 
NaCl) and B (0.1M Tris pH 8, 0.5M NaCl). After each washing step, the matrix was collected 
by centrifugation and finally poured into a Poly-Prep chromatography column. 
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The crude Spry polyclonal antibody-containing serum was diluted in 2 volume 1xPBS/0.2% 
Tween, added to the AG matrix prepared before and eluted 3x for matrix-AG-antibody 
coupling. Afterwards, the Sepharose beads were washed 3x with 12ml 1xPBS/0.2% Tween 
each. Before elution, several Eppendorf tubes were filled with 750µl neutralizing 1M 
K2HPO4. Finally, the antibody was eluted using 5ml 0.2M glycine pH2.2 to final volumes of 
1ml into the 1M K2HPO4-containing Eppendorf tubes and the antibody-positive fractions 
(checked using BioRad Protein Assay Dye Reagent) collected. Note: To avoid cross-
reactivity, antibodies against Spry1, 2 and 4 were depleted by cycling each of the 3 crude 
antisera over columns containing GST and the other Spry proteins, respectively, followed by 
affinity purification. 
 
4.11 Immunoblotting 
Cells were scraped off the culture plate, centrifuged (1000g, 3’) shock frozen in N2(l) and 
stored at -80°C until use. For protein lysis the pellet was resuspended in chilled TGH buffer 
(50mM Hepes pH7.6, 150mM NaCl, 1.5mM MgCl2, 5mM NaF, 1mM EGTA, 1% TritonX-
100, 10% glycerol, Complete (Roche), 0.5mM Na-vanadate, 1µM PMSF), incubated for 10’ 
on ice and exposed for 2’ to a sonication water bath. After centrifugation, the SN was 
collected and stored at –80°C upon use. The protein concentration was determined by spectro-
photometry using Micro BCATM Protein Assay Reagent Kit (Pierce) compared to BSA 
standards. Equal amounts of proteins were subjected to PAGE (using 37.5:1-
acrylamide:bisacrylamide for polymerization) followed by tank blotting onto nitrocellulose 
membrane. Accordingly, the membrane was probed with respective primary protein-specific, 
followed by species-specific secondary-horseradish peroxidase (HRP)-conjugated antibodies. 
The antibody-complexes were visualized by HRP-mediated light emission onto x-ray film 
using detection buffer (200mM pCoumaric acid, 1.25mM Luminol, 0.009% H2O2 in 0.1M 
Tris pH8.8) and the Western blot signals were quantified using Image Quant software 
(Molecular Dynamics). 
 
4.12 Immunoprecipitation 
Cells were lysed in TNN buffer additionally containing Complete (Roche), 0.5mM Na-
vanadate and 1µM PMSF for 10’ on ice and the SN collected after centrifugation (30’, 13000, 
4°C). 25µl Protein A Sepharose CL-4B (GE Healthcare) slurry solution (before use, beads 
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were rinsed 3x in 1xPBS, collected by centrifugation (1000g, 3’) and resuspended in 0.5 
volume 1xPBS to generate a 50% slurry) was added and incubated for 1h head over head at 
RT. Afterwards, the SN was collected by centrifugation (1000g, 3’) and incubated from 1h 
onwards head over head at RT with a specific antibody. Subsequently, 30µl 50% Sepharose 
slurry was added and the mixture incubated o/n head over head at 4°C. On the next day, the 
matrix was collected by centrifugation (1000g, 3’) and washed 5x with TNN buffer. Finally, 
the proteins were eluted and lysed by incubating the matrix 5’, 95°C in 1x sample loading 
buffer (250mM Tris pH6.8, 10% glycerine, 1.25% 2-Mercaptoethanol, 2.3% SDS, 
bromphenolblue) and collecting the SN after centrifugation. Proteins were separated by 
PAGE and visualized as described in Immunoblotting. 
 
4.13 Northern blotting and 32P-labeling 
Cells were harvested, shock frozen in N2(l) and stored at –80°C until use. For mRNA 
extraction, the pellet was resuspended in RNA lysis-buffer (100mM KCl, 10mM Tris pH7.5, 
0.5% NP-40), additionally adding 25mM EDTA, ribonucleoside vanadyl and RNAse inhibitor 
(Fermentas) and incubated for 10-30’ on ice. The mRNA-containing SN was collected by 
centrifugation (10’, 13000rpm, 4°C) and the following components added 2.8M Urea, 
0.4%SDS, 0.14M NaCl, 4mM EDTA, 4mM Tris pH7.5, 1M LiCl. The mixture was extracted 
twice with 400µl phenol:chloroform:isoamyl alcohol (49.5:49.5:1) and RNA precipitated by 
adding 0.6 volume of isopropanol. The RNA was recovered by centrifugation (30’, 
13000rpm, 4°C), washed with 70% ethanol and dried under the fume hood. Finally, the RNA 
was re-suspended in 1mM DTT, RNAse inhibitor-containing ddH2O, incubated for 5-15’ at 
68°C, and stored at –80°C until use. Note: All aqueous solutions were prepared using 
Diethylpyrocarbonat-pre-treated ddH2O. 
Equal amounts of RNA were mixed with RNA loading buffer (50% formamide, 5.9% 
formaldehyde, 6.7% glycerol, bromphenolblue in 1xMOPS (200mM MOPS, 50mM NaOAc, 
10mM EDTA) and separated by agarose gel electrophoresis using 1xMOPS, 1.85% 
formaldehyde as running buffer. Afterwards, the RNA was blotted onto nylon membrane 
using 10x SSC (1.5M NaCl, 0.15M sodium citrate) as transfer buffer by capillary force. The 
ribosomal RNAs were stained using methylen-blue solution (0.04% methylene blue in 0.5M 
NaOAc, pH5.2) to check that no degradation has occurred. Finally, the membrane was 
autocrosslinked with 120mJ for 10’’ in a Stratgene Crosslinker. If not used immediately, the 
membrane was stored in a foil at –20°C. 
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5-50ng of a purified DNA fragment was used for 32P-labeling (RediprimeTM Random Prime 
Labelling System, 32P-Nucleotides [α32P] dCTP RedivueTipTM, RT3000-250µCi, both 
Amersham Biosciences) in hybridization buffer (5xSSPE (0.9M NaCl, 50mM NaH2PO4, 
5mM EDTA, pH8), 5xDenhardt (0.1% BSA, 0.1% Polyvinylpyrolidon, 0.1% Ficoll), 0.1M 
NaHPO4, pH6.5, 50% formamide, 10mM EDTA, pH8, 1% N-Lauroylsarcosine) additionally 
containing 0.1mg/ml tRNA. After o/n incubation at 42°C using the 32P-specific probe, the 
membrane was washed 3 times for at least 20’ in cycles using wash solution I (2x SSC, 0.5% 
SDS ) and wash solution II (0,1xSSC, 0.5% SDS) at 55°C. The specific 32P-mediated mRNA 
signals were emitted on a storage phosphor screen (Amersham Biosciences) and detected via 
phosphorimager scan. Additionally, the mRNA bands were detected by x-ray film at -80°C. 
Northern blot signals were quantified using Image Quant software (Molecular Dynamics). 
 
4.14 Statistics 
Correlation analyses regarding Spry expression normalized to respective housekeeping 
controls obtained by Northern- and Immunoblot were set up by linear regression and two-
sided Mann-Whithney U-test using GraphPad Prism software. Regressions, or mean 
differences were considered as significant at P≤0.05, respectively. 
 
4.15 Construction of a human lung cDNA library 
Total RNA was extracted as described in Northern blotting. Isolation of the poly(A)+ mRNA 
fraction (Promega PolyATract mRNA Isolation System IV, Promega #Z5310) and cDNA 
library synthesis (HybriZap-2.1 XR cDNA Synthesis Kit - Stratagene #235614, HybriZap-2.1 
XR Library Construction Kit - Stratagene #235612) were performed according to the 
manufacturer’s protocol. 
 
4.16 Yeast quick trafo 
YRG-2 yeast was re-cultured on an YPAD agar plate o/n at 30°C. On the next day the yeast 
was scraped off and dissolved in 1ml ddH2O. The mixture was centrifuged for 30’’ top speed, 
the SN decanted and the following components added to the pellet to a final volume of 360µl: 
240µl 50% (w/v) polyethylenglycol 3500 (Sigma), 36µl 1M LiOAc, 50µl Salmon Sperm 
Carrier DNA [2mg/ml], 5µl pBD-Gal4-hSpry2 [0.1-1µg] and 29µl ddH2O. The 
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transformation mixture was incubated 40-60’ in a 42°C water bath. Afterwards the mixture 
was centrifuged at top speed for 30’’, the pellet resupended in 1ml ddH2O and 10µl plated on 
a selective SD-1 plate (6.7g BD-Difco yeast nitrogen base without amino acids, 182.2g D-
sorbitol, add ddH2O to 860ml, adjust to pH 5.8, add 62mg amino acids mixture –Histidine 
(His), -Leucine, -Tryptophane (Trp) (Bio 101 Systems # 4530-112), 200mg L-Adenine 
hemisulfate (Sigma #A9126), 200mg His HCl Monohydrate (Sigma #H8125), 1000mg L-
Leucine (Sigma #L8000) and 15-20g agar, autoclave, add 40ml 50% D-glucose stock 
solution). pBD-Gal4-hSpry2-containing yeast clones were grown for 3-4 days in a 30°C 
incubator. 
 
4.17 LacZ Assay 
His and LacZ reporter gene are both integrated into the YRG-2 yeast chromosome and are 
only expressed after direct interaction between two chimeras - bait protein fused to the 
reporter-binding domain and a specific library protein fused to the reporter-activating domain 
- to induce transcription. Since there can be a leaky His expression throughout the screen, the 
induction of LacZ reporter gene is the final step to identify positive clones. 
A positive pBD-Gal4-hSpry2 yeast clone was scraped-off a SD-1 plate, re-streaked onto an 
YPAD plate (20g BD-Difco peptone, 10g yeast extract, add ddH2O to 960ml, adjust to pH 
5.8, add 40mg L-Adenine hemisulfate, 15-20g agar, autoclave and add D-glucose to 2% (v/v) 
from a D-50% glucose stock solution which has been autoclaved or filter-sterilized) and 
incubate at least o/n at 30°C (for some clones it takes 1 ½ days). On the next day, the yeast 
was re-streaked onto a Whatman 1 filter paper and subjected to 4-6 rounds of freeze (N2(l)) 
and thaw (RT). Afterwards, 5.5µl β-mercaptoethanol and 34µl [20mg/ml] X-Gal (Fisher 
Biotech #BP1615-1) in DMSO was added freshly to 1.6ml Z-buffer (per liter: 16.1g 
Na2HPO4.7H2O, 16.1g NaH2PO4.H2O, 0.75g KCl, 0.246g MgSO4.7H2O, adjust to pH7, 
autoclave or filter sterilize, store at 4°C) and dropped on another Whatman 1 filter paper (for 
Ø70mm use 2ml), laid the yeast-containing filter paper face pointing up on top and incubated 
under a fume hood. Positive control yeast transformed with pBD-wt and pAD-wt vector 
should exhibit LacZ-β-galactosidase-mediated blue staining after ~90’ and negative control 
yeast transformed with pLamin C and either pBD-mut, or pAD-mut, should not stain blue 
until 8h of exposure, respectively. 
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Figure 9 Control plasmids for LacZ assay 
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Abstract 
 
Sprouty (Spry) proteins are intracellular inhibitors of RTK-signaling. Since their expression 
coincides with growth factor activity, an autoregulatory-feedback loop was postulated as 
general mechanism for controlling Spry family members’ expression. Here, we report that 
activating mutants of Ras proteins induced Spry2 and to a lesser extent Spry4 protein levels. 
In contrast, Spry1 expression was not affected by activation of Ras. Correspondingly, only 
Spry2 and Spry4 expressions were significantly elevated in cell lines harboring oncogenic K-
Ras mutations. Despite the observed elevation of Spry4 by Ras, induction of Spry4 levels 
could only be achieved by serum addition. These data demonstrate that Spry4 is influenced by 
activation of Ras, but there are additional factors involved in its regulation. The central role of 
Ras in controlling Spry2 expression was emphasized by our results illustrating that in cells 
harboring mutant Ras, growth factors were unable to induce Spry2 protein levels. In cell lines 
expressing wildtype Ras, elevation of Spry2 expression was always connected to MAPK 
activation. Corroborating, using Ras mutants specifically binding Raf or PI3K, we show that 
Spry2 expression is solely induced by MAPK pathway. Therefore we conclude that Ras 
signaling has a clearly distinguishable impact on the expression of different Spry family 
members. 
 
 
_____________________________________________________________________ Results 
 58
Introduction 
 
Deregulated cell proliferation is one of the defining features of all cancers. Hence, the critical 
balance between proliferation and growth on one hand and cell death and differentiation on 
the other hand is always disturbed. One of the pathways frequently mutated or deregulated in 
cancer involves receptor tyrosine kinase (RTK)-mediated signaling which plays an essential 
role in governing extracellular growth, proliferation and differentiation signals189. In non-
transformed cells this signaling network is precisely coordinated and integrated at any time. 
This is achieved by the implementation of several negative feedback loops which attenuate 
and terminate the cellular stimulation induced by RTK-derived signals14. 
One of these negative feedback loops includes the members of the Sprouty (Spry) protein 
family. Therefore Spry proteins are considered to play a role as tumor suppressors in several 
cancers. Consequently, various isoforms of Spry proteins have been found deregulated in 
tumors. A decrease in Spry1, Spry2 and Spry4 levels contributes to malignant transformation 
in prostate181-183. In breast cancer Spry1 and Spry2 are repressed160, and Spry2 expression 
levels are frequently downregulated in hepatocellular carcinoma159 as well as in non-small 
cell lung cancer (NSCLC)112. 
Spry was discovered as antagonist of RTK-mediated signaling in Drosophila113. Subsequent 
studies demonstrate that Spry proteins are involved in regulatory pathways counteracting 
growth factor-induced processes in several organisms including xenopus115, chicken116, 117, 
zebrafish118, mouse120 and humans122. Also mammalian Spry proteins function mainly as 
inhibitors of RTK-mediated processes, and their expression was shown to repress lung 
branching morphogenesis122, 135, angiogenesis106, 107, as well as cell growth109-112 and 
migration107, 110-112. Correspondingly, the phenotypes observed in Spry knock-out mice are 
comparable to phenotypes observed when growth factors are overexpressed during embryonic 
development141, 142, 149, 150. 
In agreement with the postulated feedback loop, Spry proteins are expressed mainly at sites of 
excessive FGF signaling during organogenesis116, 117, 134-136. Using different cell culture 
models several groups reported that Spry expression is induced in response to FGF2, EGF, 
PDGF, VEGF and HGF/SF106, 109, 111, 152, 153. In addition, loss of the GAP protein 
neurofibromin (NF-1) and expression of the oncogenic Raf1-CAAX caused an increase of 
Spry2 and Spry4 mRNA155. In accordance with these data, transgenic mice expressing the 
constitutive active K-RasG12D mutant show increased expression of Spry2 in the lung 
epithelium156. 
_____________________________________________________________________ Results 
 59
In this study we investigated the impact of Ras-induced signaling on Spry expression in 
human lung-derived cells. The presented data emphasize the influence of Ras signaling on 
Spry2 and Spry4 expression. The results demonstrate that mainly mitogen-activated protein 
kinase (MAPK) pathway activation is responsible for Spry2 induction. 
 
 
Results 
 
Expression of activated Ras induces Spry2 and Spry4 expressions. 
As an initial experiment, we tested the influence of Ras on Spry1, 2 and 4 expressions. 
Serum-starved as well as logarithmically growing WI38 cells were infected with adenoviruses 
expressing the constitutive active mutants of all three Ras family members. Using antibodies 
specifically recognizing either Spry1, Spry2 or Spry4, protein levels were measured by 
immunoblotting. Antibody-specificity was achieved by affinity chromatography (see Figure 
10). 
 
 
Figure 10 Specifity of the used Spry antibodies. 
Logarithmically growing cells were infected using adenoviruses expressing Spry1, Spry2, 
Spry4 and as a control LacZ, respectively. Cells were harvested after 2 days and equal 
amounts of protein were separated via SDS-PAGE, transferred onto nitrocellulose membrane 
and immunoblot was performed using the indicated antibodies. 
 
In addition the dominant negative forms of the three Ras proteins and the LacZ protein as 
control were included. The obtained results show that logarithmically growing  and serum-
deprived cells expressing either dominant negative H-RasS17N, K-RasS17N or N-RasS17N 
_____________________________________________________________________ Results 
 60
reduced the expression of the Spry proteins analyzed (Figure 11). In serum starved cells, only 
Spry2 and Spry4, but not Spry1 protein levels were elevated by N-RasQ61R, K-RasG12V and H-
RasG12V expression. Concerning the extent of the induction, Spry2 and Spry4 proteins 
differed. While activated Ras induced Spry2 levels about 8-fold, Spry4 protein was only 2- to 
3-fold elevated. These data demonstrate that all three activated Ras family members elevate 
Spry2 expression and to a less pronounced extent also Spry4 expression, while Spry1 
expression is not activated by Ras (Figure 11). 
 
 
Figure 11 Induction of Spry1, 2 and 4 expressions by oncogenic Ras. 
Serum-deprived and logarithmically growing WI38 cells were infected using adenoviruses 
expressing different oncogenic Ras proteins. LacZ and the respective dominant-negative 
RasS17N adenoviruses were included in the experiment. Cells were harvested after 3 days and 
equal amounts of protein were separated via SDS-PAGE, transferred onto nitrocellulose 
membrane and immunoblot was performed using the indicated antibodies. A representative 
immunoblot is shown. Protein levels were quantified by densitometry analyses and 
normalized to β-actin and serum-starved LacZ-infected cells. , serum-deprived; log, 
logarithmically growing cells. 
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NSCLC-derived tumors harboring dominant K-Ras mutations express higher levels of Spry2 
and Spry4. 
Based on these results, we analyzed if Spry protein expression correlates with constitutive 
active K-Ras mutations in different cell lines. Therefore Spry1, Spry2 and Spry4 expression 
levels were determined in 15 serum-depleted NSCLC-derived cell lines, 6 of which harbor a 
K-Ras mutation112. For normalization serum-arrested normal human lung fibroblasts WI38 
were chosen. All of the cell lines expressed the Spry proteins but the levels differed 
considerably. As shown in Figure 2, Spry1 protein levels in K-Ras mutated cell lines were 
only marginally but not significantly elevated compared to K-Ras wt tumor cell lines (2-fold), 
while both, Spry2 and Spry4 levels were clearly and significantly up-regulated in the cell lines 
harboring activating K-Ras mutations. This difference was more pronounced in case of Spry2 
(9-fold) than on Spry4 levels (6-fold). These data indicate a central role of Ras only in the 
regulation of Spry2 and Spry4, while Spry1 expression was again not elevated by endogenous 
oncogenic Ras mutations (Figure 12). Therefore Spry1 was omitted in the subsequent 
experiments. 
 
 
Figure 12 Spry1, 2 and 4 expressions in NSCLC-derived tumor cell lines. 
Endogenous Spry protein expression was analyzed in 15 NSCLC-derived tumor cell lines. All 
cells were serum-deprived for 2 days before harvesting. Equal amounts of protein were used 
for immunoblotting. After densitometric analysis the protein levels were normalized to β-
actin. WI38 cells were arbitrarily set as 1. The results are presented as box and whiskers 
diagram and statistical analyses were performed using Mann-Whitney U test. * P < 0.05. 
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Spry2 induction in response to growth factors is K-Ras dependent. 
Several reports describe a growth factor-dependent induction of Spry expression (summarized 
in136). To investigate if growth factor-induced Spry activation is solely dependent on Ras 
activation, we compared how addition of growth factors influences Spry2 and Spry4 
expression in NSCLC cell lines harboring either wild-type K-Ras or a constitutive activated 
K-RasG12 mutation. Both tumor cell lines were serum-deprived for 48 hours before growth 
factors – mainly of the FGF family – were added. Induction of ERK was measured 5 minutes 
after addition of the indicated factors and expression analyses were performed 5 hours later. 
In both cell lines, Spry4 protein levels were not altered by any of the growth factors added 
(Figure 13A, C). Also Spry2 protein levels were not induced by addition of growth factors in 
A-549 cells harboring a K-RasG12 mutation indicating that serum-deprivation failed to 
downregulate Spry2 expression. Addition of FCS caused an obvious protein shift suggesting 
protein modifications such as phosphorylation by a Ras-independent mechanism (Figure 
13B). Irrespectively of the K-Ras mutation in A549, ERK was still activated by FCS and EGF 
(Figure 13B). 
In contrast, in the K-Ras wt cell line VL-3 FCS as well as EGF caused 2- to 3-fold elevation 
of Spry2 levels in comparison to serum-deprived cells (Figure 13C). This upregulation of 
Spry2 protein was accompanied by induced activity of the MAPK pathway in response to 
FCS and EGF as monitored by measuring phosphorylated ERK levels 5 minutes after growth 
factor addition (Figure 13D). All other growth factors used (FGF2, FGF5, KGF, FGF9, 
FGF10, FGF18, PDGF and IGF) neither activated Spry2 expression (Figure 13C) nor strongly 
induced the MAPK pathway (Figure 13D). On the basis of these data we conclude that growth 
factor-induced Spry2, in contrast to Spry4, expression is dependent on activation of K-Ras. 
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Figure 13 Spry2 and 4 expressions in response to growth factors in NSCLC-derived 
tumor cells. 
A, B) K-Ras mutated A-549 and C, D) K-Ras wild-type VL-3 cells were serum-deprived for 2 
days. Before harvesting the cells, the indicated growth factors were added for 5 minutes B, D) 
and 5 hours A, C). Equal amounts were analyzed by Western Blot using the indicated 
antibodies. The ratios of Spry expression were calculated after densitometric analysis and 
normalized to β-actin and the respective serum-deprived cells. 
 
Growth factor-mediated upregulation of Spry2 expression in normal human fibroblasts 
correlates with MAPK activation. 
Next, we analyzed the influence of different growth factors on the expression of Spry2 and 
Spry4 in primary human fibroblasts (WI38 cells). Therefore WI38 cells were serum-deprived 
for 72 hours and subsequently various growth factors were added. Using immunoblot and 
Northern blot analyses we investigated Spry2 and Spry4 expression levels 5 hours after 
growth factor addition. Spry2 protein levels were induced in response to FCS, EGF, FGF2 
and FGF9, whereas FGF5, KGF, FGF10, FGF18, PDGF and IGF failed to induce Spry2 
expression. Spry4 protein was clearly induced after stimulation with FCS. The only growth 
factor which moderately increased Spry4 protein levels was EGF (Figure 14A). To explore if 
upregulation of Spry proteins is due to an induction of Spry mRNAs, serum-deprived WI38 
cells treated with FCS, EGF, FGF2 and FGF9 were compared to untreated or IGF-treated 
cells using Northern blot (Figure 14B). Induction of Spry2 and Spry4 at mRNA levels 
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reflected the results observed at the protein levels, but to a less pronounced extent. To test the 
influence of the external signals on the cellular response in WI38, activation of MAPK and 
PI3K pathway were tested by monitoring phosphorylation of ERK and rPS6 5 minutes and 20 
minutes after growth factor addition, respectively. This analysis of RTK-mediated signaling 
pathways revealed that the same growth factors - FCS, EGF, FGF2 and FGF9 - were able to 
strongly induce MAPK and PI3K pathways 5 minutes after their addition. Phosphorylation of 
rPS6 was additionally observed after stimulating the cells with IGF (Figure 14C), but 
exclusive activation of PI3K failed to induce the Spry protein expressions. These results show 
that Spry2 induction correlates strongly with MAPK activation, while Spry4 induction 
requires additional or different signals. 
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Figure 14 Growth factor-mediated induction of Spry protein and mRNA expression in 
human WI38 fibroblasts. 
Normal human WI38 fibroblasts were serum-deprived for 3 days before the indicated growth 
factors were added for A, B) 5 hours, C) (upper 2 panels) 5 minutes or C) (lower panel) 20 
minutes. Protein-lysates were prepared for Immunoblot (a) using the indicated antibodies. 
mRNA was analyzed via Northern Blot (b) using 32P-labeled full-length Spry2, Spry4 and 
rPS6 as probes. The ratios of Spry expression were calculated after densitometric analysis 
normalized to either A) β-actin or B) rPS6. Serum-deprived cells were set as 1, respectively. 
 
_____________________________________________________________________ Results 
 66
K-Ras induces Spry2 expression via the Raf-induced pathway. 
To prove that the MAPK pathway is indeed responsible for K-Ras-mediated activation of 
Spry2, we introduced constitutive active K-Ras versions carrying mutations in the effector 
loop in such ways as to exclusively bind Raf (K-RasG12V,T35S) or PI3K (K-RasG12V,Y40C), 
respectively. Starved WI38 cells were infected with viruses expressing K-RasG12V, K-
RasG12V,T35S, or K-RasG12V,Y40C, respectively. 48 hours post-infection the cells were harvested 
and analyzed concerning their effects on MAPK and PI3K pathway by measuring ERK 
phosphorylation and p110PI3K binding to Ras, respectively. In accordance with the literature, 
the K-RasG12V activated both pathways, while K-RasG12V,T35S failed to bind p110PI3K and K-
RasG12V,Y40C was unable to activate ERK (Figure 5A). Additionally, viruses expressing 
dominant negative K-RasS17N and LacZ were included. Next, the influence of the K-Ras 
mutations on Spry2 and Spry4 expression was analyzed in serum-deprived (Figure 5B, left 
column) and logarithmically growing (Figure 5B, right column) pairs of WI38 cells. 
Corroborating with the induction assays shown in Figure 4, Spry2 was exclusively induced 
when the K-Ras variants were able to activate ERK phosphorylation, while the PI3K pathway 
again failed to induce Spry2 expression. Spry4 was induced by the K-Ras mutants known to 
activate MAPK pathway, but in addition the K-Ras K-RasG12V,Y40C caused a moderate 
elevation of the Spry4 protein levels. Again Spry4 induction was less pronounced compared 
to Spry2. 
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Figure 15 The influence of K-Ras effector loop mutations on Spry2 and 4 expressions. 
A) Serum deprived WI38 cells were infected with adenoviruses expressing the indicated Ras 
mutations. A) (upper panel) Activation of Ras/MAPK was measured via immunoblot using 
phospho ERK-specific antibody and A) (lower panel) binding of Ras to PI3K was determined 
via AU5 immunoprecipitation and subsequent immunoblotting using p110PI3K antibodies. In 
parallel, Spry2 and 4 expressions were determined in B) (left panel) serum-deprived and 
logarithmically B) (right panel) growing WI38 cells infected with the indicated adenoviruses 
via immunoblotting using specific antibodies. The ratios of Spry2 and 4 were calculated via 
densitometry analyses and normalized to β-actin and LacZ-infected cells, respectively. 
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Discussion 
 
Precise regulation of signaling is critical for the coordination of cell proliferation, 
differentiation and survival. To avoid inappropriate cellular responses several inhibitory 
mechanisms operate to constrain unwanted activating events. Such regulators are the Sprouty 
family members, which were shown to be intracellular inhibitors of Ras-MAPK activation. In 
accordance to the postulated model of a negative feedback loop, Spry proteins were mainly 
found expressed at sites of excessive growth factor signaling (summarized in104, 136). 
In this report, we assessed Spry1, Spry2 and Spry4 expressions as a direct consequence of 
RTK/Ras-mediated signaling with a focus on family member-specific differences.  
Our data strongly suggest that Spry1 is not under the control of Ras-mediated signaling. The 
Spry1 protein levels are not elevated in the presence of serum. An observation which is in 
accordance with former studies106, 151, 152, describing even a decrease of Spry1 mRNA levels 
in response to growth factor induction. Additionally, ectopic expression of all three oncogenic 
Ras family members (H-RasG12V, N-RasQ61R and K-RasG12V) failed to induce Spry1 protein 
levels in logarithmically growing and in serum-deprived cells. Corroborating, Spry1 
expression in NSCLC-derived cell lines carrying a K-Ras mutation was not elevated when 
compared to lung tumor cell lines expressing wt K-Ras. Therefore we conclude that Spry1 is 
mainly regulated by Ras-independent mechanisms. One such mechanism involves the 
transcription factor WT-1 during kidney development, as published by Gross et al151. 
Nonetheless we can not completely exclude that endogenous Ras may play a minor role in the 
regulation of Spry1 expression, since the dominant-negative RasS17N variants reduced Spry1 
levels in logarithmically and serum-starved cells. In the context of the other results we assume 
that dominant negative Ras variants influence Spry1 levels by other mechanisms than by 
directly interfering with Ras.  
In contrast, Spry2 and Spry4 protein levels are clearly influenced by Ras signaling. 
Expressions of both proteins were induced by the ectopic expression of any of the three 
oncogenic Ras family members. Correspondingly, NSCLC-derived cell lines carrying a 
mutated K-Ras express significantly much higher Spry2 and Spry4 protein levels than cell 
lines derived from tumors harboring wt K-Ras. These data demonstrate that regulation of 
Spry2 and Spry4 expression is directly or indirectly dependent on Ras activation. In line with 
these data, Shaw et al. show in a recent report using mice expressing an oncogenic RasG12D 
variant in fetal lungs that Spry2 and Spry4 are increased after the knock in of the Ras 
variant156. In their report the elevation of Spry2 and Spry4 protein was comparably high, 
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while we observed that the up-regulation of Spry2 as a consequence of Ras activation was 
more pronounced than the induction of Spry4 protein levels. We assume that the observed 
differences might be a consequence of the used systems. Shaw et al. generated their data in 
mice and it is possible that there is a slight difference between the regulation of Spry proteins 
in human and in mouse. Accordingly, in another report, expression of activated Raf-1 resulted 
in a stronger upregulation of Spry2 compared to Spry4 mRNA using human BJ fibroblasts155. 
Additionally, induction of Spry2 expression proved to be sensitive to a wider range of growth 
factor signals than Spry4. Additionally, we observed that all growth factors able to induce 
ERK-phosphorylation caused an elevation of Spry2 protein levels. Spry2 activation in 
response to growth factor was observed at mRNA level even if the extent was less 
pronounced. Therefore we conclude that mechanisms at the mRNA level are involved in 
growth factor-mediated upregulation of Spry2 expression. Furthermore, these results 
demonstrate that growth factor-induced Spry2 expression is dependent on the MAPK 
pathway. Accordingly, former studies152, 153 demonstrated that growth factor (EGF, FGF2 and 
PDGF)-induced Spry2 expression could be diminished by inhibitors of MEK-1. Similar to 
their results showing that an inhibitor of PI3K pathway failed to reduce Spry2 expression, IGF 
was able to induce PI3K pathway already after 20 min, but did not augment Spry2 protein 
levels. Since in cell lines harboring activated K-Ras, Spry2 levels - irrespective of the growth 
factors’ effect on ERK phosphorylation – are no more inducible, we conclude that growth 
factors activate Spry2 expression via activation of Ras. To verify our conclusions we used K-
Ras mutations which specifically bind Raf to activate MAPK pathway or the p110 subunit of 
PI3K, respectively. These data emphasize that Ras-induced Spry2 expression is only mediated 
by Raf/ERK signals, whereas the PI3K effector pathway has no impact on Spry2.  
In contrast to the important role of ERK activation for Spry2 regulation, its impact on Spry4 is 
less distinct. Like Spry2, Spry4 was induced by ectopic expression of a Ras mutant activating 
the RAS/Raf/ERK cascade, but Spry4 was also slightly induced by a PI3K-specific Ras 
mutant. A more complex regulation of Spry4 is also emphasized by the results obtained after 
stimulation of the cells with growth factors. Spry4 protein induction was only clearly 
detectable when serum was used for stimulation. Therefore we conclude that different or 
additional signals than ERK and PI3K activation are required for elevation of Spry4 protein. 
In response to growth factor addition only EGF caused a modest twofold elevation of Spry4. 
This is in contrast to former reports which describe an induction of Spry4 mRNA in response 
to EGF, FGF and PDGF152, 153. Since we also applied Northern blots, we can exclude the 
possibility that mRNA levels are differently regulated than protein levels. The main difference 
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between our study and the other two reports is that we starved the cells for 3 days to 
synchronize them in G0/G1 phase, while Ozaki et al. serum deprived their Swiss 3T3 cells 
only for 48 hours in medium containing insulin and transferrin and Sasaki et al. added the 
growth factors to non-serum-deprived cells152, 153. This would argue that the deepness of the 
arrest decides if a certain growth factor is sufficient to induce Spry4 protein, again suggesting 
that elevation of Spry4 requires further stimuli than the one supplied by addition of a single 
growth factor. A more complex regulation of Spry4 was also indicated by published data 
showing that Wnt signaling is able to induce Spry4 expression148, 157. Therefore we suggest 
that multiple signaling pathways are able to regulate the time and extent of Spry4 expression. 
 
Summarizing, in this work we demonstrate that the mechanisms responsible for regulation of 
the different Spry proteins are clearly distinguishable. While the impact of Ras-dependent 
signaling on Spry2 and Spry4 expressions are clearly obvious and significant, additional 
factors are involved in regulating Spry4 expression. Downstream of Ras, induction of Spry2 is 
exclusively mediated by MAPK pathway. In contrast, Spry1 expression is mainly controlled 
by non-Ras-influenced mechanisms. 
 
 
Materials and Methods 
 
Patient Material and Cell Lines 
10/15 analyzed NSCLC cell lines were established at our institute: Surgical specimen from 
one histological confirmed AC (VL-1), 7 SSC (VL-3 and VL-5 - VL-10) and 2 LCC (VL-2 
and VL-4) were used at passage numbers between 15 and 30. 6/10 cell lines (VL-1 to VL-4, 
VL-9 and VL-10) were derived from primary tumors and 4 (VL5 –VL8) from lymph node 
metastases. Additionally, 5 of the adenocarcinoma cell lines (A-427, A-549, Calu-3, Calu-6 
and SK-LU-1) and the normal embryonic lung fibroblasts (WI38 at passage 16) were 
purchased from ATCC (Rockville, MD). 6/15 cell lines harbor a mutated K-Ras (VL-2, VL-4, 
A-427, A-549, Calu6, SK-LU-1). For a detailed description of the mutation analyses see 112.  
 
Antibodies 
The antisera against hSpry1, hSpry2 and hSpry4 were produced as described 112. hSpry4 was 
raised against glutathione S-transferase–tagged NH2-terminal 220 amino acids of human 
Spry4. To avoid cross-reactivity, antibodies against the other Sprys were depleted by cycling 
_____________________________________________________________________ Results 
 71
each of the 3 crude antisera over columns containing GST and the other Spry proteins, 
respectively, followed by affinity purification. Antibodies against pERK1/2, S6, p110PI3K 
were purchased from Cell Signaling (MA 01923, USA); total ERK1/2 (Acris Antibodies, 
32120 Hiddenhausen, Germany), β-actin (Novus Biologicals, CO 80160, USA), AU5 (Bethyl 
Laboratories TX 77356, USA). 
 
Immunoblotting 
Protein isolation and Immunoblotting were performed as described in 190. For protein lysis 
TGH buffer (50mM Hepes pH7.6, 150mM NaCl, 1.5mM MgCl2, 5mM NaF, 1mM EGTA, 
1% TritonX-100, 10% glycerol) was used. Western blot signals were quantified using Image 
Quant software (Molecular Dynamics). 
 
Recombinant Adenovirus Generation and Cell Infection 
Using the AU5-tagged constructs kindly provided by Dr. Rojas (Instituto de Salud Carlos III, 
Madrid, Spain) we amplified the coding sequences of human H-, K- and N-Ras wt and K-
RasG12V using the following primers: at the 5 prime end for all Ras forms the primer 5-
ATGCGGATCCATGACCGACTTCTACCTAAAGAGATCT-3 against the AU5 tag and at 
the 3 prime end 5-ATGCGAATTCTCAGGAGAGCACACACTT-3 for H-Ras,’ 5-ATGCGT 
CGACTTACATAATTACACACTTTGT-3 for K-Ras4b and 5-ATGCGAATTCTACATCAC 
CACACATGGCAA-3 for N-Ras were used and cloned into the pADlox vector, respectively. 
All mutations were introduced by PCR site-directed mutagenesis using the primers 5-GTGGG 
CGCAGTAGGTGTGGGCAAGAGTGCG-3 and 5-CCCACACCTACTGCGCCCACCACC 
ACCAG-3 for H-RasG12V, 5-GATACAGTC GGACGAGAAGAGTACAGTGCC-3 and 5-AC 
TGTACTCTTCTCGTCCAGCTGTATCGAC-3 for N-RasQ61R, 5-AAGAACGCGTTGACGA 
TACAGCTAATT-3 and 5-CAACGCGTTCTTGCCTACG CCACCAGC-3 for K-RasS17N, 5-
AAGAACGCGTTGACCATCCAGCTGATC-3 and 5- CAACGCGTTCTTGCCCACACCG 
CCGGC-3 for H-RasS17N, 5-AAAAACGCGTTGACAATCCAGCTAATC-3 and 5-CAACGC 
GTTTTTCCCAACACCACCTGC-3 for N-RasS17N, 5-CTCTATGCTAGGATCATATTCGT 
C-3 and 5-TCGACGAATATGATCCTAGCATAGAGGATTCCTACAGG-3 for K-RasS35T 
and 5-CTTCCTGCAGGAATCCTCTATGGTTGGATC-3 and 5-CCTGCAGGAAGCAAGT 
AGTAATTGAT-3 for K-RasY40C. All constructs were verified by restriction digestion and 
sequencing. 
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Recombinant viruses were produced as described190 by cotransfection of adenoviral DNA and 
the respective pADlox plasmids. If not indicated otherwise, adenoviruses were generally used 
at a multiplicity of infection of 50. 
 
Growth factors 
All growth factors used were applied in a final concentration of 10ng/ml. FGF-2, FGF-5, 
KGF, FGF10, FGF18 and IGF-1 were purchased from Strathmann Biotec AG (22459 
Hamburg, Germany), EGF from Sigma (MO 63103, USA), FGF9 from R&D Systems (MN 
55413, USA) and PDGF-AA was purchased from Chemicon International (CA 92590, USA). 
 
RNA Extraction and Northern Blotting 
RNA preparation and Northern blotting procedures followed published methods 191. For 
radioactive labeling the Rediprime Random Prime Labelling Kit (GE Healthcare, 75184 
Uppsala, Sweden) was used. As probes we used the coding sequence of hSpry2, hSpry4 and 
ribosomal protein S6 (rPS6).  
 
Immunoprecipitation 
Immunoprecipitation was performed as described in 190. 
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5.3 Unpublished data 
5.3.1 Cell cycle-specific regulation of Spry proteins 
Spry expression during cell cycle in WI38 cells 
Our further studies focused on the exact temporal expression profiles of Spry proteins during 
cell cycle progression of normal embryonic WI38 fibroblasts on mRNA and protein levels. 
Therefore, the cells were arrested in G0 by serum deprivation for 3 days in serum-free 
DMEM medium. Cell cycle block release was accomplished in medium containing 20% 
serum. At different time points after induction, cells were harvested and analyzed by flow 
cytometry, Northern- and Immunoblot. In parallel, logarithmically growing cells were 
investigated. 
According to the obtained results, selective time points were chosen to investigate Spry 
mRNA and protein levels during G0 (0 hours), early induction in G1 (4h), shortly before G1/S 
phase transition (22h), late S phase (28h) and S/G2-M transition (32h). At 42h, cell cycle in 
WI38 was already completed and re-entered G1 phase. Cell cycle progression was controlled 
via flow cytometry analysis (Figure 16a) and protein staining of cell cycle-specific CyclinD1 
(induced during G1 phase), CyclinA (highest during S/ G2 phase) and B (highest during G2-
M phase), respectively via immunoblot (Figure 16b). Our data demonstrated that hSpry1 was 
highest in G0 cells and strongly downregulated after serum induction on mRNA and protein 
levels throughout the cell cycle (Figure 16b, c). Linear regression analysis revealed that 
mRNA and protein Spry1 are co-regulated significantly (P<0.01). Spry2 mRNA and protein 
levels were downregulated during G0/G1 cell cycle arrest compared to logarithmically 
growing cells. Spry2 expression peaked in early G1 (measured 4h after induction) of the cell 
cycle, but was again repressed at the G1/S transition at 22h after serum induction. This 
downregulation was followed by a constant slope of the protein levels in S and G2 phase. 
After mitosis when cells proceed in the next G1 phase Spry2 was re-expressed. Liner 
regression analysis (P<0.05) showed that Spry2 mRNA and protein levels are co-expressed 
during cell cycle, whereas the extent of induction (normalized to serum-arrested G0/G1 cells) 
was more pronounced on protein than on mRNA levels (Figure 16b, c). At last, Spry4 mRNA 
and protein expression were both induced by serum addition early in G1. While Spry4 protein 
levels were still increased until G1/S transition and then maintained at a nearly constant 
plateau level, mRNA was found downregulated afterwards throughout the cell cycle. 
Therefore we conclude that all Spry members analyzed differed clearly in their expression 
patterns on mRNA and protein levels depending on the cell cycle stage. In the case of Spry1 
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and 2, mRNA levels represented very well the amount of protein expression suggesting that 
their expression is mainly regulated on the level of transcription. Spry4 mRNA and protein 
levels on the other hand were not co-regulated, with constant high protein levels through late 
G1, S and G2-M phase (Figure16b, c), suggesting that the amount of Spry4 protein in the cells 
is mainly influenced by translation and/or post-translational stabilization. 
 
 
Figure 16 Spry expression during cell cycle. 
WI38 cells were harvested at the indicated time points after serum addition to G0 cell cycle-
arrested cells. (a) WI38 cells were lysed and stained using propidium iodide, followed by flow 
cytometry analysis to determine cell cycle distribution of WI38. (b) Northern blot was used to 
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determine Spry mRNA levels. 32P-labeling was performed using full-length hSpry1, hSpry2, 
hSpry4 and rpS6 (housekeeping gene) cDNAs as probes, respectively. The methylen blue stain 
after capillary transfer was added as further loading control. Ratio of Spry expression levels 
were calculated normalized to rpS6 and starved cells were set arbitrarily as 1, respectively. 
(c) Immunoblot was used to determine Spry protein levels during specific phases of the cell 
cycle. Equal amounts were separated by PAGE, blotted onto nitrocellulose membrane and 
probed using the indicated antibodies. The ratio Spry expression levels were calculated 
normalized to β-actin and starved cells were set arbitrarily as 1, respectively. 
 
Spry expression between G0 and G1/S transition 
Next, we investigated the period between early G1 (4h) and G1/S transition (around 22h after 
serum addition). WI38 cells were serum-deprived and induced as described before, but 
harvested at several time points between G0 and S-phase and analyzed by immunoblot. Flow 
cytometry analysis was used to verify G1/G0 arrest in serum-deprived cells, and cell cycle 
release after serum addition for 24h (Figure 17a). 
In accordance with the data described before in Figure 16, Spry1 was shortly downregulated 
after serum induction and remained low during the remaining G1 phase. Spry4 expression 
peaked after 6h and was maintained at the same high level between 6h-24h. Accordingly, we 
could also show that Spry2 truly exhibits a biphasic expression pattern during G1 phase. In 
corroboration with our initial results, at the G0/G1 transition Spry2 protein levels increase 
constantly until 8h after induction, then the protein expression is downregulated when entering 
S phase (Figure 17b). 
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Figure 17 Spry protein expression between G0 and S phase. 
WI38 cells were harvested at the indicated time points after serum addition to G0 cell cycle-
arrested cells and processed for flow cytometry (a) and Immunoblot (b), respectively. (a) 
Flow cytometry analysis after propidium iodide staining was used to check the serum arrest 
at 0h and that cells had entered S phase at the 24h time point. (b) Cells were harvested at the 
indicated time points. Total protein was isolated, separated by PAGE and blotted onto 
nitrocellulose membrane. Spry-specific antibodies were used to detect Spry1, 2 and 4 protein 
levels, respectively. CyclinD1 and CyclinA were used, next to flow cytometry, to control 
proper cell cycle progression and β-actin was used as loading control. 
 
Regulation of Spry cell cycle expression by cCbl 
Fine tuning of signal duration and intensity is important for the cellular response to 
extracellular signals. Therefore, we next elucidated the role of the well described Spry-
interacting protein c-Cbl on the expression of Spry proteins. Whereas under normal 
conditions, c-Cbl fulfills its evolutionary conserved role as a negative regulator of signal 
transduction via a mechanism involving polyubiquitination and degradation of protein 
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tyrosine kinases, dominant-negative mutations in cCbl’s linker region lead to malignant 
transformation in vitro192. Since Spry levels differed markedly during cell cycle progression 
we investigated the role of cCbl in regulating these specific Spry expression patterns in WI38 
cells. 
Cells were arrested in G0 as described before and infected using wt (wt) and dominant 
negative ∆70Z (∆) cCbl-expressing adenoviruses, as well as LacZ (Z) control virus on the day 
of serum deprivation. In preliminary tests, it was assured that the used adenovirus titers had 
no negative impact on cell cycle characteristics and flow cytometry analyses were added in 
each experiment to check proper cell cycle progression. Again the cells were released out of 
the cell cycle block in medium containing 20% serum. At different time points after the 
induction, cells were harvested and analyzed by flow cytometry (Figure 18a) and immunoblot 
(Figure 18b), respectively. 
Cell cycle-specific Spry protein levels in cells overexpressing LacZ control virus was in 
accordance to the protein patterns described before (Figure 16, 17). Our data revealed that 
cCbl wt and ∆70Z protein increased Spry1 expression throughout the cell cycle (Figure 18b). 
A possible explanation is the ectopic expression of active and dominant-negative cCbl protein 
influence other, unknown regulators of Spry1 leading to higher expression levels. Spry4 
protein was also induced by both cCbl forms in serum-deprived cells. During later G1 stages 
overexpression of either cCbl wt or cCbl ∆70Z protein, respectively had no effect Spry4 
protein (Figure 18b). In the case of Spry2, ectopic expression of cCbl wt further reduced 
Spry2 protein, whereas dominant negative cCbl ∆70Z protein markedly increased Spry2 
expression (Figure 18b). Therefore, our data clearly indicate that cCbl proteins are involved in 
repressing Spry2 expression before G1/S transition, whereas having a different and/ or 
opposing effect on Spry1 and Spry4. 
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Figure 18 Influnce of cCbl on Spry cell cycle 
(a) Flow cytometry analysis of cells harvested after 1h and 24h of induction. (b) Cells were 
harvested at the indicated time points. Total protein was isolated, separated by PAGE and 
blotted onto nitrocellulose membrane. Spry-specific antibodies were used to detect Spry1, 2 
and 4 protein levels, respectively. β-actin was used as loading control. wt, cCbl wt. 
∆, dominant negative cCbl ∆70Z. Z, LacZ control virus. 
 
5.3.2 Construction of a human lung cDNA library 
To identify novel interaction partners of Spry2, a human lung cDNA library was synthesized 
in order to be used in Yeast-two hybrid screening assays. 
1mg of total RNA was isolated from diverse logarithmically growing WI38 and NSCLC-
derived fibroblasts and cells enriched in distinct phases of the cell cycle (G0, G1, S, or G2/M 
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phase). The accuracy was checked via gel electrophoresis and the amount measured via η-
drop measurement. 
poly(A)+ mRNA was captured via biotinylated-oligo(dT) probes and streptavidin 
paramagnetic particles (SA-PMPs) and eluted by ddH20 to recover 6.4µg poly(A)+ mRNA. 
The sample was restricted to final volume of 52µl (123ng/µl) using SpeedVac centrifugation 
at 30°C. 1st strand PCR synthesis was performed using oligo(dT) linker-primer followed by 
2nd strand PCR reaction. After restriction digestion, the proceeded cDNA was size 
fractionated via size-exclusion chromatography (Figure 19). 
 
short exposure long exposure  
Fraction 1    2    3    4    5     7    9    11  13 6      8    10   12
 
Figure 19 cDNA size fractionation. 
Bulk cDNA separated by agarose gel electrophoresis (between 1.5-2.0kbps) (left panels) and 
size fractionated cDNAs separated by PAGE (right panels). 
 
The cDNA fractions 4-6 and 7-12 were combined and extracted via phenol/chloroform. 
Afterwards the two samples were ligated into the phagemid vector HybriZAP-2.1 vector and 
packaged (Gigapack III Gold Packaging Extract - Stratagene #200201, Gigapack III Plus 
Packaging Extract - Stratagene #200205) generating a “long” (L) and “short” (S) primary 
phagemid cDNA library, respectively. Both were titrated to determine the plaque forming 
units (pfu)/ml (Figure 20). 
 
titer primary phagemid library: L (1.7x106 pfu/ml), S (9.9x105 pfu/ml) 
 
 
Figure 20 Plaque-Assay used to titer the phagemid library. 
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Further, PCR reaction was used to determine the percentage and cDNA insert sizes of both 
primary libraries, respectively. The insert sizes of the primary library L varied between 500-
2000bps, with an insert percentage of 100% (Note: sample 9, 10, 15, 17, 18 - PCR did not 
work). The insert sizes of the primary library S varied between 300-1000bps, with an insert 
percentage of about 50% (Figure 21). 
 
LONG
SHORT
M M
M
M M  
Figure 21 PCR verification of percentage and insert size. 
PCR products which are >237 bps in length represent the HybriZAP-2.1 vector with an 
cDNA insert, PCR products which are 237 bps in length represent empty HybriZAP-2.1 
vector. M marker. 
 
Both, primary libraries were amplified in XL-1 Blue MRF’ to multiple L and S 
bacteriophage-derived secondary libraries. Each time the pfu/ml was determined 
 
titer secondary phagemid library:  L-a 5.0x109 pfu/ml, L-b 2.4x1011 pfu/ml, L-c 2.3x1010 
pfu/ml, L-d 1.3x1010 pfu/ml 
 
S-a 2.0x108 pfu/ml, S-b 1.3x1010 pfu/ml, S-c 6.2x109 
pfu/ml 
 
Next, both 2nd phagemid libraries were amplified in XL-1 Blue MRF’ cells and subsequently 
mass excised to pAD-GAL4-2.1 phagemid libraries, respectively, using an ExAssist Helper 
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Phage. The excised phagemids were titrated (colony forming units (cfu)/ml) and the 
percentage and cDNA insert sizes determined via PCR. The inset sizes in library L varied 
between 0.5-4.0 kbps and in S between 0.25-1.5 kpbs. The percentage of inserted cDNA 
fragments was in both pAD-GAL4-2.1 phagemid libraries close to 100% (Figure 22). 
 
titer pAD-GAL4-2.1 phagemid library: L-a 2.6x108 cfu/ml, S-a 7.4x107 cfu/ml 
 
LONG
 
SHORT
 
Figure 22 PCR verification of percentage and insert size after mass excision. 
PCR products which are >237 bps in length represent the HybriZAP-2.1 vector with insert, 
PCR product which are 237 bps in length represent empty HybriZAP-2.1 vector. 
 
Finally, L and S pAD-GAL4-2.1 phagemid libraries were amplified in XLOLR cells and 
isolated via MAXI Prep (Figure 23), respectively, to be used in a Yeast-two Hybrid Screen. 
 
purified pAD-GAL4-2.1-cDNA vectors: L-a 1: 450ng/µl (200µl), L-a 2: 640ng/µl (180µl), 
L-a 3: 1.4µg/µl (200µl), L-a 4: 820ng/µl (250µl), 
L-a 5: 540ng/µl (250µl), L-a 6: 1.3µg/µl (250µl) 
 
S-a 1: 830ng/µl (200µl), S-a 2: 1.3µg/µl (250µl), 
S-a 3: 880ng/µl (250µl) 
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Figure 23 MAXIPreps cDNA library. 
L-a 1-6 and S-a 1-3 after EcoRI digestion. Note the length of the pAD-GAL4-2.1-cDNA 
plasmids were 9-10kbps. 
 
5.3.3 pBD-Gal4-hSpry2 bait LacZ screen 
hSpry2 coding sequence was amplified by PCR using specific primers (5-AGTCGAATTCAT 
GGAGGCCAGAGCTCAGAG-3 and 5-AGTCGTCGACCTATGTTGGTTTTTCAAAGT-3), 
cloned into the pBD-Gal4 bait vector and isolation of a positive clone was verified by 
sequencing. Then, pBD-Gal4- hSpry2 was transformed into YRG-2 yeast, plated on a SD-1 (-
Trp) plate and incubated for 3-4 days in a 30°C incubator. 
Using the LacZ assay, it was determined that Spry2 bait protein was not showing any auto- 
activity (by forming blue colonies) and therefore is suitable to successfully screen for 
interacting proteins in a yeast-two hybrid screen (Figure 24). 
 
 
Figure 24 Spry2 LacZ assay. 
LacZ assay of Spry2 bait (red square) after 5.5 hours in comparison to the positive (+) and 
negative (-) controls. 
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6 Summary and Discussion 
 
In the industrial world, cancer is the second highest cause of death after cardiovascular 
diseases. Although neoplastic transformation can be regarded as a disease of aging (the 
incidences increase with age) the pathogenic basis for developing tumours lies earlier in life193 
and theoretically any normal cell can become a cancer cell. Carcinogenesis is mediated via a 
multistep process accumulating genetic alterations for selective advantage194, 195. Even if 
cancer cells are very divergent concerning cell morphology and genetic instability, 
transformation of a normal to a tumor cell is characterized by a few characteristic features, 
such as enhanced mobility (migration and metastasis), autonomous growth and proliferation, 
and decreased cell immortality. Under non-malignant conditions, all these characetristics are 
tightly regulated by signal transduction pathways which convert extracellular signals into 
specific cellular responses14. Such signal-promoting cascades have to be tightly regulated to 
limit the negative consequences of abberant activation, such as malformations during 
development and tumor formation during adult life. Thereby, negative feedback loops 
functioning to attenuate and terminate signaling processes play a central role. One of these 
negative feedback loops includes the members of the Spry protein family113, 130, 139, 140. Spry 
was first discovered in a Drosophila genetic screen as a novel antagonist of FGF-induced 
tracheal branching113. Homologues of Spry were found in Xenopus laevis115, chicken116, 117, 
zebrafish118, rat119, mouse116, 120, 121 and humans113, 122 based on sequence similarities. During 
organogenesis, Spry proteins are mainly expressed at sites of excessive FGF signaling 
organogenesis116, 117, 134-136. Further, induction of Spry expression, as well as Spry fuction was 
shown to be mediated by diverse growth factor stimuli, such as FGF2, EGF, PDGF, VEGF 
and HGF/SF106, 109, 111, 152, 153. Upon activation Spry proteins are localized to the plasma 
membrane and function mainly as inhibitors of RTK/Ras/MAPK-mediated processes to 
inhibit branching processes during embryogenesis, cell proliferation as well as cell growth 
and migration105. Correspondingly, the phenotypes observed in Spry knock-out mice are 
comparable to phenotypes observed when growth factors are overexpressed during embryonic 
development 141, 142, 149, 150. Only in response to EGF signaling in mammalians, ectopically 
expressed Spry sustained MAPK induction106, 126, 128, 166, 170-172. In this specific case, activated 
Spry was targeted and degraded by the ubiquitin E3 ligase cCbl instead of phosphorylated 
EGFR leading to prolonged EGFR-mediated signaling128, 175.  
In human cancers, one of the systems almost generally found deregulated is the 
RTK/Ras/MAPK pathway. Consequently, multiple studies described tumor promoting 
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alterations in proteins functioning within this cascade, such as hyper-activated RTKs, or 
mutated Ras and bRaf189, 196, 197-201. Additionally, negative regulators, such as PTEN and c-
Cbl, which guarantee multicellular surveillance, possess a high tumour suppressing potency22, 
202, 203 and are often found deregulated or lost in cancer. In this context, the aim of the study 
was to clarify the role of Spry proteins as negative regulators of RTK-mediated signaling.  
 
In this study we report that expression of Spry2 is consistently downregulated on mRNA and 
protein levels in NSCLC compared to the respective normal adjacent epithelium. According 
to previous studies in rodents135, 204, Spry2 was primarly expressed in normal bronchial 
epithelium. Lowered levels of Spry2 protein, as found in NSCLC tumor specimens, are likely 
to cause a selective growth advantage of tumor cells. In contrast to Spry2, Spry1 even tended 
to be elevated in some tumor samples. The same situation was found in HCC159, 184, where 
Spry2 but not Spry1 was identified to be downregulated. In the prior report, Spry2 was 
downregulated in 9 of 11 (82%) specimens, whereas Spry1 was upregulated in 8/11 (73%) 
HCC samples compared to paired non-malignant liver159. With regard to other solid tumor 
types, it was shown that both Spry1 (38/50, 78%) and Spry2 (48/50, 96%) expression levels 
are frequently repressed in breast cancer160, while in prostate cancer a decrease in Spry1 (39% 
of 407 immunohistochemically analyzed prostate cancer tissue microarrays) and Spry4 (11 
out of 25 cases, 44%) levels contribute to malignant transformation181, 183. Further, Spry2 
expression was markedly reduced in metastasis-forming prostate cancer-derived sublines 
compared to their respective two parent prostate cancer cell lines182. These data indicate that 
diverse members of the signal-limitting family of Spry proteins are commonly downregulated 
during carcinogenesis, whereas which and how many of the Spry members are affected, 
depends on the tissue origin. 
Many different mechanisms may account for Spry2 downregulation in NSCLC. Since it was 
shown that in prostate cancer cells (but not in breast cancer- and HCC-derived cells159, 160) 
silencing by promoter hypermethylation accounted for the reduced expression of Spry2182, 
and in some cases also for Spry4183, we checked the response of Spry2 expression in NSCLC-
derived cells to treatment using AZA, which demethylates silenced promoter-regions to 
induce transcription. In our hands, only 3/12 cell lines exhibited slightly enhanced Spry2 
expression following incubation in AZA-containg medium. Further, reduced gene doses did 
not significantly account for reduced Spry2 levels in NSCLC cells (data not shown). Contrary, 
in HCC, Spry2 was frequently deleted at the genomic DNA level184 and in prostate cancer, 
27-40% of LOH was analyzed using tightly flanking markers to the Spry2 gene182. 
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Nevertheless, as shown in both Manuscripts of this thesis, enhanced Spry2 and Spry4 levels 
correlated with activating K-Ras mutations, whereas Spry1 expression was only slightly 
upregulated in the background of constitutively active Ras. Using RFLP analyses, we solely 
detected K-Ras mutations in the NSCLC histological subtypes of adenocarcinoma (AC) and 
large-cell carcinoma (LCC), but non in squameous cell carcinoma (SCC). Correspondingly, 
K-Ras mutations were almost exclusively described in AC/ LCC and not in SCC58. Since 
Spry expression is regulated as part of an auto-regulatory feedback loop105, activating Ras 
mutations might explain why, with respect to histological subtypes, Spry2 levels tend to be 
higher in AC- and LCC- than in SCC-derived cell lines. Induced levels of Spry2 were also 
found in mice expressing dominant active K-RasG12D 156. Furthermore, in melanoma cells 
expressing dominant active B-RafV599E, Spry2 was also upregulated compared to low levels in 
melanocytes and wt B-Raf melanoma cells186. Nevertheless, the mechanisms responsible for 
downregulation of Spry2 in NSCLC cancer have to be elucidated in further, more mechanistic 
approaches. 
To assess the contribution of Spry2 downregulation to the malignant phenotype of NSCLC 
cells, we investigated the effect of ectopically expressed Spry2 on inhibition of MAPK 
activity, cell migration and proliferation. Using an adenoviral expressing system, we 
demonstrated that Spry2-mediated repression of ERK activity was exclusively observed in 
those cells homozygous for K-Raswt in contrast to mutated K-RasG12. Also, in another report, 
Spry family member Spry4 failed to inhibit constitutive active RasL61 MAPK activation107. 
Accordingly, deceleration of cell migration by Spry2 was significantly more potent in NSCLC 
cell lines expressing K-Raswt as compared to cell lines harboring K-RasG12mut. Since initial 
attempts to immunoprecipitate Spry2 with K-Ras have been unsuccessful (data not shown) 
our data give further evidence that Spry proteins counteract RTK-Ras-MAPK-mediated 
signaling upstream of Ras. Focusing on MAPK activity and cell migration, reduced Spry 
proteins only serves as an selective advantage in cells expressing wt Ras during neoplastic 
formation, whereas constitutively active Ras can circumvent Spry2 MAPK inhibition. Further, 
Ras-MAPK induced Spry overexpression might be tolerated when activating mutations occur 
at the level or downstream of Ras.  
Interestingly, cell proliferation was significantly inhibited by Spry2 in all tested NSCLC cell 
lines irrespective of the K-Ras status and completely abolished tumor formation in SCID 
mice. Also in urethane-induced NSCLC tumor development in mice185 overexpression of 
Spry2 reduced tumor multiplicity and diameter in lung. Surprisingly, ectopic expression of 
dominant negative Spry2 (Spry2Y55F) unable to inhibit MAPK activation132, 153, also 
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significantly attenuated NSCLC cell proliferation. Nevertheless the effect was lower 
compared to overexpressed wt Spry2 protein, arguing for a possible cumulating contribution 
of MAPK-mediated signals. In the mutated K-Ras cell line A-549, a difference in the 
inhibition of cell proliferation between wt Spry2 and Spry2Y55F became visible from 72 hours 
onwards. Since activated K-Ras is lost due to degradation (reported half life of around 30 
hours205) we suggest that Spry2wt, but not Spry2Y55F, interferes with the activation also of 
newly synthesized K-Ras. Nevertheless, we were the first to show that also Spry2Y55F 
significantly inhibits cell proliferation and suggest that at least Spry2 counteracts growth-
factor induced cellular responses in a Ras-dependent and –independent manner by a yet 
unidentified mechanism. Since a study suggested the involvement of PTEN in Spry2-
mediated effects206, we also checked the activity of PI3K-downstream signaling components. 
In our cells, AKT and S6 phosphorylations were rather increased by ectopic Spry2 which was 
also seen in a report studying the influence of Spry2 during muscle cell development207. 
Therefore, and in accordance with several other reports136, we conclude that also during 
NSCLC tumorigenesis, Spry2 expression is not involved in counteracting PI3K-mediated 
signals.  
 
In our subsequent studies we focused on different mechanisms regulating Spry1, 2 and 4 
expressions. Since all Spry family members were described to function and to be regulated in 
an autoregulatory feedback loop manner, our data proof the existence of distinct Spry 
member-specific differences. 
Focusing on Spry1 we propose regulating mechanisms independent of the RTK/Ras/MAPK 
cascade. Elevated levels of Spry1 were found exclusively in serum-deprived, G0-resting cells, 
whereas a decrease of Spry1 mRNA and protein expression was observed immediately after 
cell cycle release and low levels were maintained throughout the remaining phases of the cell 
cycle. Also in other studies Spry1 mRNA levels were decreased as a consequence of growth 
factor induction106, 151, 152. Further, Spry1 protein levels were only slightly but not significantly 
enhanced by activating Ras mutations. Interestingly, dominant-negative versions of Ras 
moderately repressed Spry1 levels. Since Ras functions via divergent downstream cascades, it 
seems that inhibited signal transmission has secondary effects also on components involved in 
Spry1 regulation. Other data described the tumor suppressing transcription factor WT-1 to 
activate Spry1 promotor during kidney development151. Surprisingly, overexpression of both, 
wt and oncogenic cCbl, enhanced Spry1 expression during cell cycle. Since it was shown that 
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Spry1 is targeted by cCbl132 our data indicate that cCbl stabilizes Spry1 by yet undefined 
mechanisms. 
Induction of Spry2 expression is dominantly influenced via Ras/MAPK-mediated cascades. 
Using different approaches we detected upregulated Spry2 especially in those cell lines 
harboring activating Ras mutations. Further, ectopically expressed Ras proteins elevated 
Spry2 protein levels in serum-deprived and logarithmically growing cells. In earlier reports, 
knock in of an oncogenic RasG12D variant in fetal lungs of mice as well as fibroblasts 
expressing active Raf-1 also caused increased Spry2 protein levels compared to wt cells155, 156. 
In resting cells, we were able to induce Spry2 expression in response to serum and EGF, 
FGF2 and FGF9 growth factor addition as a consequence of immediate Erk activation. 
Further, the induction of Spry2 expression was co-regulated on mRNA and protein levels. 
Since these growth stimuli also induced signaling via PI3K pathway, we used oncogenic Ras 
versions exclusively signaling either via MAPK or PI3K, to demonstrate that induction is 
exclusevly mediated via the Ras/Erk signaling cascade. Accordingly, IGF, exclusively 
activating PI3K and not MAPK, failed to induce Spry2. An earlier report also showed that Erk 
activation is required for Spry2 expression, since Spry2 levels are decreased upon inhibition 
of MEK-1152, 153. On the other hand, Spry2 could not be further elevated in a cell line 
harboring activated Ras. Since serum still increased the slow migrating band, it is possible 
that some of the post-translational modifications such as phosphorylation105 or 
farnesylation106 are mediated by Ras-independent mechanisms. During cell cycle, again Spry2 
mRNA and proteins levels were significantly co-regulated. Interstingly, Spry2 expression was 
upregulated early in G1 phase, downregulated before G1/S transition and peaked again during 
late S and G2/M phase. Introduction of ectopic wt cCbl did not interfere with upregulation of 
Spry2 after cell cycle release, but further reduced Spry2 levels before G1/S transition. Since 
cells expressing dominat-negative (oncogenic) cCbl failed to downregulate Spry2 expression, 
we propose that degradation of Spry2 via cCbl is crucial before cell entry into S-phase. 
Oncogenic cCbl ∆70Z lacks the linker region between cCbl’s tyrosine binding and RING 
finger domain and was shown to induce rapid and acute transformation of NIH3T3192. Since 
the linker is thought to mediate multiple interactions between the bound substrate of cCbl and 
the unbiquitine-conjugating enzymes recruited by cCbl’s RING finger, cCbl ∆70Z is unable to 
multi-ubiquitylate and downregulate RTKs208. Also in the case of Spry2, cCbl ∆70Z interferes 
with the ability of cCbl wt to mediate Spry2 ubiquitination. 
In the literature, Spry4 was shown to be upregulated in response to activating mutations of 
Ras and within the MAPK cascade155, 156. In our studies, we also elucidated that Ras signaling 
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influences Spry4 expression. Comparable to Spry2, Spry4 was also upregulated in NSCLC 
cells harboring constitutively active Ras. Further, introduction of activating Ras proteins 
elevated Spry4 levels in both serum-deprived and logarithmically growing cells. Nevertheless, 
Spry4 induction was always less pronounced than Spry2. Testing the influence of diverse 
growth stimuli on Spry4 expression in response to Erk and PI3K activation in resting cells, 
Spry4 was only efficiently induced after serum addition on mRNA and protein levels. Despite 
of a slight increase of Spry4 upon EGF stimulation, all other growth factors used (including 
many FGFs, IGF and PDGF) failed to induce Spry4. Other reports described immediate 
induction of Spry4 expression in response to Wnt3a and Wnt7a and Fzd9 coexpression148, 157, 
while it was also reported that Spry4 mRNA is upregulated in response to EGF, FGF and 
PDGF and directly linked to Erk activation152, 153. In these reports, Spry4 expression was 
analyzed in cells starved for 48h in medium containing insulin and transferrin or to non-
starved cells152, 153. In our hands, Spry4 does not fulfill the criteria of functioning as an 
immediate early gene. Since we assured that diverse growth factors were only applied to G0-
resting cells, it is possible that unequal methodical approaches account for the differences 
seen in the case of Spry4 induction. Using activating Ras mutations exclusively targeting 
either Raf or PI3K, respectively, we could show that both Ras-dowmstream effector cascades 
elevate Spry4 levels in 72 hours serum-deprived cells and suggest that induction, extent and 
duration of Spry4 are differently regulated by diverse signaling pathways next to Erk 
activation. During cell cycle, Spry4 protein does not mimic the expression pattern of Spry4 
mRNA. While Spry4 mRNA only peaked early in G1 and remained low during other cell 
cycle phases, Spry4 protein expression was enhanced during G1 (6-8h after serum addition in 
WI38 cells) remained high throughout the remaining cell cycle. Therefore, we suggest that 
Spry4 induction is dependent on diverse stimuli besides MAPK activation (achieved by the 
addition of single growth factors to G0 WI38 cells), while, once elevated, post-translatory 
events are responsible to stabilize Spry4 protein. Using ectopically expressed wt and 
oncogenic cCbl, Spry4 protein was moderately induced in G0/G1 cells by wt cCbl and even 
more by dominant negative cCbl. Nevertheless, before G1/S transition the high Spry4 
expression peak was not much influenced by the cCbl proteins used. Since Spry4 was shown 
not to be a target of cCbl, it seems that according to the influence of different cCbl proteins on 
Spry1, cCbl alters the activities of other proteins influencing Spry4 protein expression. 
 
In summary we could show that loss of Spry2 and not Spry1 expression contributes to the 
malignant phenotype of NSCLC by enhancing RTK-mediated processes like cell migration 
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and proliferation and propose that Spry2 re-expression might serve as a promising therapy of 
NSCLC even when K-Ras is mutated. Further we were able to point out differences 
concerning induction and regulation of different Spry family members. In our systems, only 
Spry2 mRNA and protein were exclusively activated by the Ras/Erk pathway. We could also 
show that downregulation via cCbl is occuring during G1 phase before G1/S transition. While 
Spry4 protein is stabilized by mechanisms secondary to Ras activation, Spry1 is 
downregulated by a yet unidentified mechanism. Since we demonstrate that Spry2 inhibits 
RTK-mediated signals upstream of Ras but also by mechanisms independent of the 
Ras/MAPK signaling axis, possibly via inhibiting Ca2+-efflux115 in response to Ras-
independen activation of phospholipase-C209, the identification of new interaction partners 
will be necessary to clearly dissect function and regulation of Spry proteins. Corrspondingly, 
we synthesized a human lung cDNA library suitable for Yeast-two hybrid screening using 
Spry proteins as baits. 
We conclude that Spry proteins are important players to regulate cell and tissue homeostasis 
and in the future, activation of Spry proteins might be considered as a strategy for novel 
approaches in cancer therapy. 
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7 Abbreviations 
 
4E-BP   eIF4E-binding protein 
AC   adenocarcinoma 
AP2   activator protein 2 
AZA   5-aza-2'-deoxycytidine 
Bnl   branchless 
Btl   breathless 
CAKUT  congenital anomalies of the urinary tract and kidney 
cCbl   casitas B-lineage lymphoma 
CREB   cyclicAMP response element-binding protein 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
eIF4E   eukaryotic translation initiation factor 
ER   endoplasmic reticulum 
Erk   extracellular-regulated kinase 
FGF   fibroblast growth factor 
FGFR   FGF receptor 
FRS2   fibroblast growth factor receptor substrate 2 
GAP   GTPase activating proteins 
GDNF   glial cell line-derived neurotrophic factor 
GEF   guanine-nucleotide exchange factor 
Grb2   growth factor receptor-bound protein 2 
GTPases  monomeric guanosine triphosphotases 
HCC   hepatocellular carcinoma 
HGF/ SF  hepatocyte growth factor/ scatter factor 
HIF-1   hypoxia-inducible factor 1 
Htl   heartless 
LCC   large-cell carcinoma 
LOH   loss of heterozygosity 
MAPK  mitogen-activated protein kinase 
MEFs   mouse embryonic fibroblasts 
Mnk-1   MAPK-interacting kinase 1 
MOI   multiplicity of infection 
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NF1   neurofibromin-1 
NSCLC  non–small cell lung cancer (Nicht-kleinzelliges Lungenkarzinom) 
PCR   polymerase chain reaction 
PDGF   platelet-derived growth factor 
PDK-1   3’-phosphoinositide-dependent kinase-1 
PH   pleckstrin-homology 
PI3K   phosphatidylinositol 3-kinase 
PIP2   phosphatidylinositol 3, 4-biphosphate 
PIP3   phosphatidylinositol 3, 4, 5-triphosphate 
PKB   Akt/protein kinase B 
PP2A   protein phosphatase 2A 
pSer, pTyr  phosphorylated serine, tyrosine residue 
PTB   phospho-tyrosine binding 
PTP1B  protein-Tyr phosphatase-1B 
PTEN   phosphatase and tensin homolog 
Ret   rearranged during transfection 
RT   room temperature 
RTK   receptor tyrosine kinase 
SCC   squameous cell carcinoma 
Ser   serine 
SH2/ 3   Src homology region 2/ 3 
Shh   sonic hedgehog homolog 
Shp2   SH2-containing Tyr phosphatase 2 
Sos   son of sevenless 
SP1   stimulating protein 1 
Spry   sprouty  
Stat   signal transducer and activator of transcription 
Tesk   serine/threonine testicular protein kinase 
Tyr   tyrosine 
VEGF   vascular-endothelial growth factor 
VEGFR  VEGF receptor 
wt   wildtype (wildtyp) 
WT1   wilms tumor suppressor gene 1 
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